HUT64012A

Process for producing benzene derivatives promoting nerve growth factor productiion, as well as pharmaceutical compositions comprising such active ingredient

Abstract

This record has no abstract on file.

HUT64012A, drawing sheet 1 — Sheet 1 of 17

Term

No projected expiry on record.

15 claims: 2 independent, 13 dependent

1
Patent claims:Szabadalmi igénypontok: 1. Eljárás (I) általános képletű vegyületek - a képletben First A process for the preparation of compounds of formula (I) R1 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővel helyettesített aminocsoport, védett aminocsoport vagy nitrocsoport, R1 an amino group, an amino group substituted with 1 or 2 A substituents, a protected amino group or a nitro group, R2 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővei helyettesített aminocsoport, védett aminocsoport, hidroxicsoport, A csoportba tartozó helyettesítővei helyettesített hidroxicsoport vagy védett hidroxicsoport;R2 an amino group, an amino group substituted with 1 or 2 group A substituents, a protected amino group, a hydroxy group, a hydroxy group substituted with a group A substituent or a protected hydroxy group;R3 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővei helyettesített aminocsoport, védett aminocsoport, gyűrűnitrogénatomon keresztül kapcsolódó heterogyűrűs csoport vagy gyűrűnitrogénatomon keresztül kapcsolódó és 1 vagy 2 A vagy B csoportba tartozó helyettesítővei helyettesített heterogyűrűs csoport;R3 an amino group, an amino group substituted with 1 or 2 A substituents, a protected amino group, a heterocyclic group attached via a ring nitrogen atom or a heterocyclic group substituted via a ring nitrogen atom and substituted with 1 or 2 A or B groups;m o és 2 közötti egész szám;mo is an integer between 2 and 2;n 0 és 6 közötti egész szám;n is an integer from 0 to 6;Group A substitutes: az A csoportba tartozó helyettesítők: alkilcsoport, 1-3 halogénatomot tartalmazó halogén-alkilcsoport, cikloalkilcsoport, 1-3 B vagy C csoportba tartozó helyettesítővel helyettesített cikloalkilcsoport, arilcsoport, 1-3 B vagy C csoportba tartozó helyettesítővei helyettesített arilcsoport, aralkilcsoport, legalább egy, 1-3 B vagy C csoportba tartozó helyettesítővei helyettesített arilcsoportot tartalmazó alkyl, haloalkyl having 1 to 3 halogens, cycloalkyl, cycloalkyl substituted with 1 to 3 B or C substituents, aryl, aryl substituted with 1 to 3 B or C, aralkyl, at least one of 1 to 3 B or C aryl substituted with a substituent of Group 4 · 4 · - 75 aralkilcsoport, heterogyűrűs csoport, 1-3 B vagy C csoportba tartozó helyettesítővel helyettesített heterogyűrűs csoport;- 75 aralkyl, heterocyclic group, heterocyclic group substituted with 1-3 groups B or C;Group B substitutes: a B csoportba tartozó helyettesítők: halogen atom, alkoxy group, alkoxycarbonyl group, nitro group, cyano group, arylcarbonyl group and aralkylcarbonyl group;and group C substitutes: halogénatom, alkoxicsosport, alkoxi-karbonil-csoport, nitrocsoport, cianocsoport, aril-karbonil-csoport és aralkil-karbonilcsoport;és a C csoportba tartozó helyettesítők: alkilcsoport, 1-3 halogénatomot tartalmazó halogén-alkil-csoport és cikloalkilcsoport;alkyl, haloalkyl having 1 to 3 halogens and cycloalkyl;a heterogyűrűs csoportok 5-7-tagú heterogyűrűs csoportok, amelyek 1-4 heteroatomként nitrogén-, oxigén- vagy kénatomot tartalmaznak, adott esetben 1 vagy 2 arilgyűrűvel kondenzáltak;heterocyclic groups are 5-7 membered heterocyclic groups containing 1-4 heteroatoms nitrogen, oxygen or sulfur, optionally fused to 1 or 2 aryl rings;alkyl groups are straight-chain or branched C 1 -C 6 alkyl groups;az alkilcsoportok egyenes vagy elágazó szénláncú 1-6 szénatomos alkilcsoportok;a halogénalkilcsoportok 1-3 halogénatommal helyettesített alkilcsoportok;haloalkyl groups are alkyl groups substituted with 1 to 3 halogens;a cikloalkilcsoportok 3-10-tagú, adott esetben áthidalt telített gyűrűs szénhidrogéncsoportok;cycloalkyl groups are 3- to 10-membered, optionally bridged, saturated cyclic hydrocarbon groups;aryl groups are 6 to 14 membered aromatic ring hydrocarbons optionally fused to cycloalkyl;az arilcsoportok 6-14 - tagú aromás gyűrűs szénhidrogéncsoportok, amelyek adott esetben cikloalkilcsoporttal kondenzáltak;aralkyl groups are alkyl groups substituted with 1-3 aryl groups;az aralkilcsoportok 1-3 arilcsoporttal helyettesített alkilcsoportok;a halogénatomok fluor-, klór-, bróm- vagy jódatomok;halogen atoms are fluorine, chlorine, bromine or iodine;alkoxy groups have straight or branched carbon chains of 1 to 6 carbon · 1 · 6 · · · · · · · · ································································ · ···· alkoxy groups;az alkoxicsoportok egyenes vagy elágazó szénláncú 1-6 szén• · · · · · · ····· · · · · • · · · · · ·· • ····· ·· · ··· · · · ··· ·· atomos alkoxicsoportok;azzal a megkötéssel, hogy ha m értéke 0, akkor n értéke 2 és 6 közötti egész szám vagy sóik előállítására, azzal jellemezve, hogy egy (II) általános képletű karbonsav reakcióképes származékát, a képletben RÍ' nitrocsoport, 1 vagy 2, a fentebb meghatározott A csoportba tartozó helyettesítővel helyettesített aminocsoport, vagy védett aminocsoport;R2· 1 vagy 2, a fentebb meghatározott A csoportba tartozó helyettesítővel helyettesített aminocsoport, védett aminocsoport, a fentebb meghatározott A csoportba tartozó helyettesítővel helyettesített hidroxicsoport vagy védett hidroxicsoport;Y kilépőcsoport;és m és n jelentése a fenti, egy (III) általános képletű vegyülettel, amelyben R3 jelentése a fenti, amidképzési reakcióban reagáltatunk, így egy (I') általános képletű vegyületet kapunk, amelyben R1', R2', R3, m és n jelentése a fenti, és szükséges vagy kívánt esetben a terméken a következő lépések közül egyet vagy többet elvégzünk: with the proviso that when m is 0, n is an integer from 2 to 6, or a salt thereof, wherein the reactive derivative of a carboxylic acid of formula II wherein R1 is nitro, 1 or 2 as defined above An amino group substituted with a substituent belonging to the group, or a protected amino group;R2 · 1 or 2 amino groups substituted with a group A substituent as defined above, protected amino group, hydroxy group substituted with substituent group A above or protected hydroxy group;Y is a leaving group;and m and n are as defined above for a compound of formula (III) wherein R3 is as described above in the amide formation reaction to give a compound of formula (I ') wherein R1', R2', R3, m and n are as defined above, and if necessary or desired, the product is subjected to one or more of the following steps: (1) ha R1' jelentése nitrocsoport, redukcióval olyan (I) általános képletű vegyületté alakítjuk, amelyben R1 jelentése aminocsopport, (2) ha R1' jelentése védett aminocsoport, a védőcsoportot eltávolítjuk, (3) ha R2' védett aminocsoport vagy védett hidroxicsoport, a védőcsoportot eltávolítjuk, és/vagy (4) sót képzünk. (1) if R1'is a nitro group, reduced to a compound of formula I wherein R1 is an amino group, (2) if R1'is a protected amino group, the protecting group is removed (3) when R2protected amino group or protected hydroxy group, the protecting group is removed and / or (4) salt is formed.
15
(I) általános képletű vegyületek, amely képletben R1 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővei helyettesített aminocsoport, védett aminocsoport • «W 9 999 • · · · · ·· »» • 999 9 9 999 • · *··· 9 99 ··· ·· « 99999 vagy nitrocsoport, 15th Compounds of formula (I) wherein R1 amino group, amino group substituted with 1 or 2 group A, protected amino group • 999 9 999 • · 99999 or nitro group . R2 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővei helyettesített aminocsoport, védett aminocsoport, hidroxicsoport, A csoportba tartozó helyettesítővei helyettesített hidroxicsoport vagy védett hidroxicsoport; R2 an amino group, an amino group substituted with 1 or 2 group A substituents, a protected amino group, a hydroxy group, a hydroxy group substituted with a group A substituent or a protected hydroxy group; R3 aminocsoport, 1 vagy 2 A csoportba tartozó helyettesítővei helyettesített aminocsoport, védett aminocsoport, gyűrűnitrogénatömön keresztül kapcsolódó heterogyűrűs csoport vagy gyűrűnitrogénatomon keresztül kapcsolódó és 1 vagy 2 A vagy B csoportba tartozó helyettesítővei helyettesített heterogyűrűs csoport; R3 an amino group, an amino group substituted with 1 or 2 A substituents, a protected amino group, a heterocyclic group linked through a ring nitrogen atom or a heterocyclic group substituted via a ring nitrogen atom and substituted with 1 or 2 A or B groups; m 0 és 2 közötti egész szám; m is an integer from 0 to 2; n 0 és 6 közötti egész szám; n is an integer from 0 to 6; Group A substitutes:az A csoportba tartozó helyettesítők: alkilcsoport, 1-3 halogénatomot tartalmazó halogén-alkilcsoport, cikloalkilcsoport, 1-3 B vagy C csoportba tartozó helyettesítővel helyettesített cikloalkilcsoport, arilcsoport, 1-3 B vagy C csoportba tartozó helyettesítővei helyettesített arilcsoport, aralkilcsoport, legalább egy, 1-3 B vagy C csoportba tartozó helyettesítővei helyettesített arilcsoportot tartalmazó aralkilcsoport, heterogyűrűs csoport, 1-3 B vagy C csoportba tartozó helyettesítővel helyettesített heterogyűrűs csoport;alkyl, haloalkyl having 1 to 3 halogens, cycloalkyl, cycloalkyl substituted with 1 to 3 B or C substituents, aryl, aryl substituted with 1 to 3 B or C, aralkyl, at least one of 1 to 3 B or C aralkyl substituted with a substituent on group A, a heterocyclic group, a heterocyclic group substituted with 1-3 groups B or C;Group B substitutes: a B csoportba tartozó helyettesítők: a halogen atom, an alkoxy group, an alkoxycarbonyl group, a nitro group, a cyano group, an arylcarbonyl group and an aralkylcarbonyl group;and group C substitutes: halogénatom, alkoxicsosport, alkoxi-karbonil-csoport, ·· ’·· · · • ···· nitrocsoport, cianocsoport, aril-karbonil-csoport és aralkil-karbonilcsoport;és a C csoportba tartozó helyettesítők: alkilcsoport, 1-3 halogénatomot tartalmazó halogén-alkil-csoport és cikloalkilcsoport;alkyl, haloalkyl having 1 to 3 halogens and cycloalkyl;a heterogyűrűs csoportok 5-7-tagú heterogyűrűs csoportok, amelyek 1-4 heteroatomként nitrogén-, oxigén- vagy kénatomot tartalmaznak, adott esetben 1 vagy 2 arilgyűrűvel kondenzáltak;heterocyclic groups are 5-7 membered heterocyclic groups containing 1-4 heteroatoms nitrogen, oxygen or sulfur, optionally fused to 1 or 2 aryl rings;alkyl groups are straight-chain or branched C 1 -C 6 alkyl groups;az alkilcsoportok egyenes vagy elágazó szénláncú 1-6 szénatomos alkilcsoportok;a halogénalkilcsoportok 1-3 halogénatommal helyettesített alkilcsoportok;haloalkyl groups are alkyl groups substituted with 1 to 3 halogens;a cikloalkilcsoportok 3-10-tagú, adott esetben áthidalt telített gyűrűs szénhidrogéncsoportok;cycloalkyl groups are 3- to 10-membered, optionally bridged, saturated cyclic hydrocarbon groups;aryl groups are 6 to 14 membered aromatic ring hydrocarbons optionally fused to cycloalkyl;az arilcsoportok 6-14 - tagú aromás gyűrűs szénhidrogéncsoportok, amelyek adott esetben cikloalkilcsoporttal kondenzáltak;aralkyl groups are alkyl groups substituted with 1-3 aryl groups;az aralkilcsoportok 1-3 arilcsoporttal helyettesített alkilcsoportok ;a halogénatomok fluor-, klór-, bróm- vagy jódatomok;halogen atoms are fluorine, chlorine, bromine or iodine;alkoxy groups are linear or branched C 1 -C 6 alkoxy groups;az alkoxicsoportok egyenes vagy elágazó szénláncú 1-6 szénatomos alkoxicsoportok;azzal a megkötéssel, hogy ha m értéke 0, akkor n értéke 2 és with the proviso that if m is 0 then n is 2 and 6 and their salts. 6 közötti egész szám és sóik.

Independent claims2

716 paragraphs, as filed

The present invention relates to novel benzene derivatives which promote the production or secretion of nerve growth factor (abbreviated NGF), but have a minor side effect.

The discovery of NGF was reported in 1954 by Levi-Montaleini et al. NGF is a nourishing and growth factor required to maintain the growth and function of nerve tissue. More recently, in animal studies, it has become known that NGF accelerates the healing of damaged peripheral nerve tissue and that NGF is also effective in treating central nervous dysfunction, particularly Alzheimer's disease and cerebral ischemia.

However, NGF is a high molecular weight protein (13,000 in monomeric form, 26,000 in dimeric form), and thus there are generally concerns regarding its administration as a drug and safety.

It is also known that catechol neurotransmitters, such as adrenaline and noradrenaline, and catechol analogues, may promote the formation of NGF. These compounds have side effects that are particularly evident in nerve stimulation.

European Patent Publication No. 399,814, issued November 28, 1990, discloses phenyl derivatives that promote the production and secretion of human nerve growth factor. Compounds with similar activity and structure are described in Japanese Patent Application Laid-Open No. 1-217211, filed August 25, 1989, and

1991st On April 9, 2008, it was published under number 3-83921 without investigation.

It is an object of the present invention to provide benzene derivatives which promote the formation of nerve growth factor as an effective drug or can be used as an intermediate in the preparation of such an active drug. It is a further object of the present invention to provide active ingredients which have less side effects and, in particular, less nervous excitement. It is a further object of the present invention to provide pharmaceutical compositions for use in the treatment of peripheral nerve injuries and disorders affecting the functioning of the brain nervous system, in particular Alzheimer's disease and cerebral ischemia.

The present invention provides novel compounds of formula I in the formula

R1 an amino group, an amino group substituted by 1 or 2 A substituents, a protected amino group or a nitro group,

R2 an amino group, an amino group substituted with 1 or 2 A substituents, a protected amino group, a hydroxy group, a hydroxy group substituted with a A group or a protected hydroxy group;

R3 an amino group, an amino group substituted with 1 or 2 A substituents, a protected amino group, a heterocyclic group attached via a ring nitrogen atom or a ring nitrogen atom.

a bonded heterocyclic group substituted with 1 or 2 A or 2 substituents;

m is an integer from 0 to 2;

n is an integer from 0 to 6;

Group A substitutes:

alkyl, 1-3 haloalkyl, cycloalkyl, 1-3 B or C substituted cycloalkyl, aryl, 1-3 B or C substituted aryl, aralkyl, at least one 1-3 An aralkyl group substituted with a B or C substituent, a heterocyclic group, a heterocyclic group substituted with 1-3 B or C substituents;

Group B substitutes:

halogen, alkoxy, alkoxycarbonyl, nitro, cyano, arylcarbonyl and aralkylcarbonyl; and group C substitutes:

alkyl, haloalkyl having 1 to 3 halogens and cycloalkyl;

with the proviso that when m is 0, n is an integer from 2 to 6 and their salts.

Compounds of formula I wherein R1 denotes a nitro group, those compounds of formula I:. t .:. ··.

- 5 intermediates in which R1 represents an amino group.

In the definition of the compounds of the present invention, alkyl groups are generally straight or branched C 1 -C 6 alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, , isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, η-hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methyl pentyl, 3,3-dimethyl-butyl, 2,2-dimethyl-butyl, 1,1-dimethyl-butyl, 1,2-dimethyl-butyl, 1,3-dimethyl-butyl, 2,3-dimethylbutyl or 2-ethylbutyl. Preferred alkyl groups are straight or branched C 1 -C 4 alkyl groups.

In the definition of compounds of the present invention, cycloalkyl groups are typically 3- to 10-membered saturated cyclic hydrocarbon groups which may be bridged, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl or adamantyl. Preferred cycloalkyl groups are 5-10 membered, optionally bridged, saturated cyclic hydrocarbon groups. A particularly preferred cycloalkyl group is adamantyl.

Aryl groups in the definition of the compounds of the present invention are typically 6 to 14 membered aromatic cyclic hydrocarbon groups such as phenyl, naphthyl, phenanthrenyl or anthracenyl; phenyl is preferred. The aryl group may also be fused to a 3- to 10-membered cycloalkyl group such as 2-indanyl.

In the definition of compounds of the present invention: 4

- 6 aralkyl groups typically consist of an alkyl group substituted with 1-3 aryl groups. Examples of such groups are benzyl, naphthylmethyl, indenylmethyl, phenanthrenylmethyl, anthracenylmethyl, diphenylmethyl, triphenylmethyl, 1-phenylethyl, 2-phenylethyl, , 1-naphthyl-ethyl, 2-naphthyl-ethyl, 1-phenyl-propyl, 2-phenyl-propyl, 3-phenyl-propyl, 1-naphthyl-propyl, 2-naphthyl-propyl, 3-naphthyl-propyl, 1-phenyl-butyl, 2-phenyl-butyl, 3-phenyl-butyl, 4-phenyl-butyl, 1-naphthyl-butyl, 2-naphthyl-butyl, 3 naphthyl butyl, 4-naphthyl butyl, 1-phenylpentyl, 2-phenylpentyl, 3-phenylpentyl, 4-phenyl-pentyl, 5-phenyl-pentyl, 1-naphthyl-pentyl, 2-naphthyl-pentyl, 3-naphthyl-pentyl, 4-naphthyl-pentyl, 5-naphthyl-pentyl, -phenyl-hexyl, 2-phenyl-hexyl, 3-phenyl-hexyl, 4-phenyl-hexyl, 5-phenyl-hexyl, 6-phenyl-hexyl, 1-naphthyl-hexyl, 2- naphthylhexyl, 3-naphthylhexyl, 4-naphthylhexyl, 5-naphthylhexyl or 6-naphthylhexyl. Preferred aralkyl groups have from one to four carbon atoms in their alkyl moiety. A particularly preferred aralkyl group is benzyl.

Heterocyclic groups in the definition of compounds of the present invention are generally 5-7 membered fused heterocyclic groups containing from 1 to 4 nitrogen, oxygen or sulfur atoms. Heterocyclic groups which are required to contain one nitrogen atom as the point of attachment may have more than one nitrogen heteroatom. Heterocyclic groups are aromatic and partially or fully saturated and are condensed with 1 or 2 aryl rings, usually 1 or 2 benzene rings, · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·· ·· · ··· · ·

- 7 weeks.

Heterocyclic groups which generally include heterocyclic groups and those containing a ring nitrogen atom as a point of attachment are typically aromatic heterocyclic groups such as furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazole -, isoxazolyl, thiazolyl, isothiazolyl,

1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; partially or fully reduced heterocyclic groups such as morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl or piperazinyl; fused aromatic heterocyclic groups such as isobenzfuranyl, benzothienyl, tetrahydrobenzothienyl, chromenyl, xanthenyl, phenoxanthenyl, indolidinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolidinyl, quinolyl, isoquinolyl, , naphthyridinyl, quinoxalinyl, quinazolinyl, carbazolyl, carbolinyl, acridinyl or isoindolinyl; or partially or fully saturated fused heterocyclic groups such as tetrahydrobenzothienyl.

Preferred are 5- to 7-membered heterocyclic groups containing at least one nitrogen atom and optionally another sulfur or oxygen atom which may be partially or fully saturated and optionally fused to an aryl ring. Such preferred heterocyclic groups include: aromatic heterocyclic groups such as aromatic heterocyclic groups.

pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; a partially or fully saturated heterocyclic group such as morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl or piperazinyl; or fused heterocyclic groups such as quinolyl or benzothienyl.

Particularly preferred heterocyclic groups are imidazolyl, oxazolyl, isoxazolyl, thiazolyl, piperidyl and piperazyl.

Suitably, halogen atoms are fluorine, chlorine, bromine or iodine in the definition of compounds of the present invention.

In the definition of compounds of the present invention, alkoxy groups typically consist of the above alkyl group and an oxygen atom and may be straight or branched C 1 -C 6 alkoxy groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentoxy, isopentoxy, 2-methylbutoxy, neopentoxy, hexyloxy, 4-methylpentoxy, 3-methylpentoxy, 2-methylpentoxy -, 3,3-dimethyl-butoxy, 2,2-dimethyl-butoxy, 1,1-dimethyl-butoxy, 1,2-dimethyl-butoxy,

1,3-dimethylbutoxy or 2,3-dimethylbutoxy. Preferred are straight or branched C 1 -C 4 alkoxy groups.

• 4 4 4 ·· · ··« 4 4 4··· • 4 · · · 4 ·4 · • «4444 444

444 44 4 44444

Halogenalkyl groups in the definition of compounds of the present invention typically include an alkyl group and 1 to 3 halogens, such as trifluoromethyl, trichloromethyl, difluoromethyl, dichloromethyl, dibromomethyl, fluoromethyl. , 2,2,2-trichloroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl, 2-chloroethyl, 2-fluoroethyl or 2,2-dibromo- ethyl. A preferred haloalkyl group is a halomethyl group. Trifluoromethyl is particularly preferred.

The protected amino groups which are R1 and / or R2 are protected by 1 or 2 amino protecting groups. The designation of the protecting group is not of particular importance and is typically a protecting group commonly used for protecting an amino group, preferably, for example:

an aliphatic acyl group such as a C 1-20 alkanoyl group including formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, pivaloyl, valeryl, isovaleryl, octanoyl, lauroyl, myristoyl, tridecanoyl -, a palmitoyl or stearoyl group, a halogenated aliphatic acyl group, in particular a C 1 -C 6 haloalkanoyl group containing 13 halogen atoms such as chloroacetyl, dichloroacetyl, trichloroacetyl or trifluoroacetyl, an aliphatic acyl group substituted by an alkoxy group, more particularly in the alkoxy moiety and in the alkanoyl moiety a C 1-6 alkoxyalkanoyl group such as methoxyacetyl, an unsaturated aliphatic acyl group, in particular a C 3-6 alkenoyl group such as (E) -2-methyl-2 butenoyl group; an aromatic acyl group such as an arylcarbonyl group, for example ben? · * 4 44 «♦ * 4 · 4 4 4 4 4

4·4 4 444

44··· 444 • 44 44 4 4 4 444

- 10 -oyl, alpha-naphthoyl or beta-naphthoyl, haloarylcarbonyl, more particularly a haloarylcarbonyl group containing from 1 to 3 halogens, such as 2-bromobenzoyl or 4-chlorobenzoyl, an alkylarylcarbonyl group, more particularly an alkylarylcarbonyl group containing from 1 to 3 alkyl substituents, wherein each alkyl moiety contains from 1 to 3 carbon atoms, such as 2,4,5-trimethylbenzoyl or 4-toluoyl, alkoxylarylcarbonyl, more particularly 13 alkoxy-arylcarbonyl groups having 13 alkoxy substituents, and each alkoxy group having 1 to 3 carbon atoms, e.g. 4-anisoyl, nitroarylcarbonyl, more particularly 1 or 2 nitro-arylcarbonyl groups such as 4-nitrobenzoyl - or a 2-nitrobenzoyl group, an alkoxycarbonylarylcarbonyl group, more particularly an alkoxycarbonylarylcarbonyl group containing 1 or 2 alkoxycarbonyl groups; wherein each of the alkoxy groups contains from 1 to 3 carbon atoms, such as 2- (methoxycarbonyl) benzoyl, arylarylcarbonyl such as 4-phenyl-benzoyl;

an alkoxycarbonyl group consisting of an alkoxy group and a carbonyl group may have from 2 to 7 carbon atoms and may be straight or branched, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxyl; carbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentoxycarbonyl, isopentoxycarbonyl, 2-methylbutoxycarbonyl, neopentoxycarbonyl, hexyloxycarbonyl, , 4-methylpentoxycarbonyl, 3-methyl • ·

- 11-pentoxycarbonyl, 2-methylpentoxycarbonyl, 3,3-dimethylbutoxycarbonyl, 2,2-dimethylbutoxycarbonyl, 1,1-dimethylbutoxycarbonyl, 1,2-dimethylbutoxycarbonyl, 1,3-dimethylbutoxycarbonyl or 2,3-dimethylbutoxycarbonyl, preferably straight or branched C 2 -C 5 alkoxycarbonyl, haloalkoxycarbonyl , more particularly, a haloalkoxy group in which the alkyl moiety contains 1 to 6 carbon atoms and 1 to 3 halogen atoms, such as 2,2,2-trichloroethoxycarbonyl or a trialkylsilylalkoxy group, more particularly a trialkylsilylalkoxy group in which the alkyl groups and alkoxy groups each contain from 1 to 6 carbon atoms such as 2- (trimethyl) silyl) ethoxycarbonyl group;

an alkenyloxycarbonyl group, in particular an alkenyloxycarbonyl group in which the alkenyl group contains from 2 to 6 carbon atoms, such as vinyloxycarbonyl or allyloxycarbonyl; optionally substituted aralkyloxycarbonyl, more particularly an aralkyloxycarbonyl group in which the aryl ring is substituted with 1-3 C 1-6 alkoxy or 1 or 2 nitro groups such as benzyloxycarbonyl, 4-methoxybenzyloxy; carbonyl,

3,4-dimethoxybenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl or 4-nitrobenzyloxycarbonyl;

a silyl group such as a trialkylsilyl group, each of which has an alkyl group of 1 to 6 carbon atoms, such as trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, methyldiisopropylsilyl, , methyl-di «4 ·.:. ··. :

• ·«··<.' · ·· • ·«··· ·· · ··· ·· · «·· · ·

- 12-tert-butylsilyl or triisopropylsilyl, or tri-substituted silyl substituted with alkyl and aryl having 1 or 2 C 1 -C 6 alkyl groups and 2 or 1 aryl groups respectively, such as diphenylmethylsilyl -, diphenylbutylsilyl, diphenylisopropylsilyl or phenyldiisopropylsilyl;

an amino acid residue such as alanyl, glycyl, glutamyl or asparaginyl;

Schiff-substituted substituted methylene groups such as Ν, Ν-dimethylaminomethylene, benzylidene, 4-methoxybenzylidene, 4-nitrobenzylidene, salicylidene, 5-chlorosalicylidene, diphenylmethylene- or (5-chloro-2-hydroxyphenyl) phenylmethylene.

Of these preferred amino protecting groups, aliphatic acyl groups or aromatic acyl groups or amino acid residues are most preferred.

The protected hydroxy group is R2 may include a protecting group suitable for protecting a hydroxy group in a chemical reaction or a hydroxy protecting group that hydrolyzes in vivo when the drug is administered. In the former case, the compounds of the formula I are synthetic intermediates. In the latter case, the compound of formula (I) is a prodrug. What protecting group is chosen is irrelevant, typically protecting groups commonly used for protecting a hydroxy group are used, for example:

for synthetic intermediates:

• 4 · 4 * · «• 44 · · · 4 · · · · · · · 4 · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · an aromatic acyl group as defined above; tetrahydropyranyl or tetrahydrothiopyranyl optionally substituted with 1 or 2 C 1 -C 6 alkoxy groups or 1 or 2 halogen atoms, such as tetrahydropyran-2-yl, 3-bromo-tetrahydropyran-2-yl, 4-methoxy-tetrahydropyran- 4-yl, tetrahydrothiopyran-2-yl or 4-methoxy-tetrahydrothiopyran-4-yl; tetrahydrofuranyl or tetrahydrothiofuranyl, such as tetrahydrofuran-2-yl or tetrahydrothiofuran-2-yl; a silyl group as defined above; an alkoxymethyl group such as a C 1-6 alkoxy group in the alkoxy moiety such as methoxymethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl - or a tert-butoxymethyl group, an alkoxyalkoxymethyl group, in particular an alkoxyalkoxymethyl group, each of which has an alkoxy group of 1 to 6 carbon atoms, for example 2-methoxyethoxymethyl group, in particular mono- or di- (haloalkoxy) methyl, containing 1 to 6 carbon atoms in the alkoxy group and substituted with 1 to 3 halogens, such as 2,2,2-trichloroethoxymethyl or bis (2-chloroethoxy) methyl; substituted ethyl group, in particular an alkoxy or haloalkoxyethyl group containing from 1 to 6 carbon atoms in the alkoxy moiety and substituted with 0-3 halogen atoms, such as 1-ethoxyethyl or 1- (isopropoxy) ethyl or 2, 2,2-trichloro-ethyl; an alkoxycarbonyl group as defined above; an alkenyloxycarbonyl group as defined above; or an aralkyloxycarbonyl group; or pro-drug:

an amino acid residue such as alanyl, glycyl, glutamyl or asparaginyl or, for example, pivaloyloxymethyloxycarbonyl.

Of these preferred hydroxy protecting groups, the aliphatic acyl group, the aromatic acyl group, the aralkyl group or the in vivo readily hydrolyzable protecting group used to prepare the injectable drug are particularly preferred.

R3 is a heterocyclic group which is bonded through a nitrogen atom in its ring and may be substituted as defined, suitably an optionally fused 5- to 7-membered heterocyclic group containing 1 to 2 additional heteroatoms, such as nitrogen, may contain oxygen or sulfur. This heterocyclic group may be aromatic or partially or fully saturated and fused to 1 or 2 aryl rings, usually 1 or 2 benzene rings.

A preferred heterocyclic group is, for example, an aromatic heterocyclic group such as pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl or pyrazinyl; a partially or fully saturated heterocyclic group such as morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl or piperazinyl, preferably morpholinyl, thiomorpholinyl, piperidinyl or piperidinyl; or a fused heterocyclic group such as indolidinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolidinyl, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, carbazolyl or carbolinyl.

Preferred examples of amino groups substituted by 1-2A include those substituted with 1 or 2 straight or branched alkyl groups such as methylamino, ethylamino, propylamino, isopropylamino, butyl, and the like. amino, isobutylamino, dimethylamino, diethylamino or methylethylamino; an example of an amino group substituted with a C 1-4 alkyl group and a 6-10 membered aromatic cyclic hydrocarbon group is methylphenylamino, ethylphenylamino, propylphenylamino, isopropylphenylamino, butyl -phenylamino, isobutylphenylamino; one or two 5-10 membered amino groups optionally substituted by a bridged saturated cyclic hydrocarbon group, for example, cyclopentylamino, cyclohexylamino or 1-adamantylamino; an amino group substituted with one or two 6 to 10 membered aromatic ring hydrocarbyl groups optionally fused to a cycloalkyl group and optionally substituted with 1 or 2 of the B or C substituents, an arylamino group such as phenyl amino, diphenylamino, 1-indanylamino or naphthylamino; a haloarylamino group such as 2-fluorophenylamino, 3-bromophenylamino, 4-fluoro- phenylamino, 2-fluoroindan-1-ylamino, 3,4-Difluoro-phenylamino-, ♦ · f · '· * · · · · · · · · · · · · · · · · · · · · ·

2,4-difluorophenylamino, 2,5-difluorophenylamino, 2-chlorophenylamino, 3-chlorophenylamino, 4-chlorophenylamino,

3,4-dichlorophenylamino, 2,4-dichlorophenylamino, 2,5-dichlorophenylamino or 2-fluoronaphthylamino, (C1-C4 alkoxy) -arylamino such as 2-ethoxyphenylamino, 3-propoxyphenylamino, 4-methoxyphenylamino, 3,4-dimethoxyphenylamino, 2,4-dimethoxyphenylamino, e.g. , 2,5-dimethoxyphenylamino or 2-methoxynaphthylamino, nitroarylamino such as 2-nitrophenylamino, 3-nitrophenylamino or 4-nitrophenyl -amino, cyano-arylamino, for example 2-cyanophenylamino, 3-cyanophenylamino or 4-cyanophenylamino, benzoylarylamino such as 2-benzoylphenylamino, 3-benzoylphenyl amino, 4-benzoyl-phenylamino or 2-benzoyl-naphthylamino, halo-C 1-4 -alkyl-arylamino, such as 2- (trifluoromethyl) -phenylamino; - (trichloromethyl) phenylamino, 4- (trifluoromethyl) phenylamino, 2,4-di (trifluoromethyl) phenylamino or 2,5-di (trifluoromethyl) ) -phenylamino, (C 1 -C 4 alkyl) arylamino such as 2-methylphenylamino, 3-methylphenylamino,

4-methylphenylamino, 3,4-dimethylphenylamino, 2,4-dimethylphenylamino, 2,5-dimethylphenylamino, 2-ethylphenylamino- , 3-propylphenylamino, 4-butylphenylamino, 3,4-diethylphenylamino , 2,4-diethylphenylamino, 2,5-dipropylphenyl- amino, 3,4,5-trimethylphenylamino or 2-methylnaphthylamino; 1 or an amino group substituted with 2 heterocyclic groups, such as tetrahydrobenzothiophen-2-ylamino, 4-η ,-, quinoline-; 2-ylamino, quinolin-3-ylamino, quinolin-5-ylamino, quinolin-8-ylamino, pyridin-2-ylamino, pyridin-3-yl-a -mino, pyridin-4-ylamino, morpholin-2-ylamino, morpholin-3-ylamino, piperidin-2-ylamino, piperidin-3-ylamino, piperidine -4-ylamino, piperazin-2-ylamino or piperazin-3-ylamino; 1 or an amino group substituted with 2 heterocyclic groups substituted with 1 or 2 B or C substituents, such as a halo-heterocyclylamino group such as 3-fluoro-tetrahydrobenzothiophen-2-ylamino, 3-bromopiperidin-4 -yl-amino, 2-fluoro-quinolin-3-ylamino, 3-fluoro-morpholin-2-ylamino, 3-fluoro-piperazin-2-ylamino, 2-chloro-piperidine -4-ylamino, 3-chloro-tetrahydro-benzothiophen-2-ylamino, 4-chloro-piperidin-2-ylamino or 2,6-dichloro-piperidin-4-ylamino, (C1-C4-alkoxy) -heterocyclyl-amino, for example 3-ethoxy-morpholin-2-yl- amino, 4-methoxy-quinolin-5-ylamino or 2,6-dimethoxy-piperidin-4-ylamino, (C2-C5-alkoxy) -carbonyl-heterocyclylamino, such as 3- (methoxy- carbonyl) tetrahydro-benzothiophen-2-ylamino or 4- (ethoxycarbonyl) -tetrahydrobenzothiophen-2-ylamino, cyano-heterocyclyl-amino, for example 3-cyanopyridin-2-ylamino, 3-cyano-tetrahydro-benzothiophen-2-ylamino or 3-cyano-piperazin-2-ylamino, halo (C 1 -C 4) alkyl-heterocyclyl- amino groups such as 2- (trifluoromethyl) quinolin-3-ylamino, 3- (trichloromethyl) methylmorpholin-2-ylamino, 4- (trifluoromethyl) tetrahydro-benzothiophene-2 -ylamino or 2,6-di (trifluoro18)

methyl) piperidin-4-ylamino or (C 1-4 alkyl) heterocyclyl amino such as 3-methyl tetrahydrobenzothiophen-2-ylamino, 4-methyl tetrahydro-benzothiophen-2-ylamino, , 4-methylpiperidin-2-ylamino, 2,6-dimethylpyridin-4-ylamino or 2,5-dimethylpyridin-4-ylamino.

Preferred examples of hydroxy groups substituted with substituent A include hydroxy groups substituted with straight or branched C 1 -C 4 alkyl groups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy or isobutoxy; aralkyl-substituted hydroxy groups, i.e. aralkoxy groups such as benzyloxy, phenethyloxy or diphenylmethyloxy.

Substituted heterocyclic groups containing a nitrogen atom as a point of attachment and substituted with 1 or 2 A or B substituents include, for example, halogen substituted 5- or 6-membered heterocyclic groups such as 3-bromopiperidino, 3-fluoro- morpholino, 2-fluoro-piperazino, 2-chloro-piperidino, 4-chloro-piperidino or 2,4-dichloro-piperidino; 5- or 6-membered heterocyclic groups substituted with C 1-4 alkoxy, such as 2-ethoxymorpholino or 3,4-dimethoxypiperidino; 5- or 6-membered heterocyclic groups substituted with C2-C5 alkoxycarbonyl groups such as 2- (methoxycarbonyl) morpholino or 2- (methoxycarbonyl) piperazino; a nitro substituted 5- or 6-membered heterocyclic group such as 3-nitro-piperidino; a 5- or 6-membered heterocyclic group substituted with cyano 19 such as 4-cyanopiperidino or 3-cyanopiperazino; a benzoyl-substituted 5- or 6-membered heterocyclic group such as 2-benzoylpiperidino; a 5- or 6-membered heterocyclic group substituted with halo (C 1 -C 4 alkyl) such as 3- (trichloromethyl) morpholine or 2,5-di (trifluoromethyl) piperidino; A 5- or 6-membered heterocyclic group substituted with C 1-4 alkyl such as 4-methylpiperidino, 2-ethylpiperidino or 3-pyrrolidino; or a 5- or 6-membered heterocyclic group substituted with a C 5 -C 10 cycloalkyl group such as 4-cyclohexylpiperidino.

Preferred examples of C 5 -C 10 cycloalkyl groups substituted with 1-3 B or C are halo (C 5 -C 10 cycloalkyl) groups such as 2-chlorocyclopentyl, 3-chlorocyclopentyl, 2-fluorocyclo. pentyl, 3-fluoro-cyclopentyl, 2-chloro-cyclohexyl, 3-fluoro-cyclohexyl, 4-bromo-cyclohexyl, 3,4-difluoro-cyclohexyl, 2-fluoro-adamantyl or 3- fluoro-adamantyl group; C 1-4 alkoxy (C 5-10 cycloalkyl) such as 2-methoxycyclopentyl, 3-ethoxycyclopentyl;f 2-propoxycyclohexyl, 3-methoxycyclohexyl, 4-methoxycyclohexyl,

2-methoxyadamantyl or 3-ethoxyadamantyl; a (C 2 -C 5) alkoxycarbonyl (C 5 -C 10) cycloalkyl group such as 2- (methoxycarbonyl) cyclopentyl, 3- (ethoxycarbonyl) cyclopentyl, 2- (methoxycarbonyl); ) -cyclohexyl, 3- (methoxycarbonyl) -cyclohexyl, 4- (ethoxycarbonyl) -cyclohexyl, 2- (propoxycarbonyl) -adamantyl or 4- (methoxycarbonyl) -adamantyl- group; a nitro (C 5 -C 10 cycloalkyl) group such as 2-nitrocyclopentyl, 3-nitrocyclopentyl, 2-nitrocyclohexyl, 3-nitrocyclohexyl, 4-nitrocyclohexyl, nitro-adamantyl or 3-nitro-adamantyl; cyano (C 5 -C 10 cycloalkyl) such as 2-cyanocyclopentyl, 3-cyanocyclopentyl, 2-cyanocyclohexyl, cyanocyclohexyl, 4-cyanocyclohexyl, 2-cyano-adamantyl or 4-cyano-adamantyl; benzoyl (C 5 -C 10 cycloalkyl) such as 3-benzoyl-cyclopentyl, 3-benzoyl-cyclohexyl, 4-benzoyl-cyclohexyl or 2-benzoyl-adamantyl; halogen (C 1 -C 4 alkyl) (C 5 -C 10 cycloalkyl) groups such as 3- (trifluoroethyl) cyclopentyl, 4- (trichloromethyl) cyclohexyl, 2- (trifluoro) methyl) adamantyl or 3- (trifluoromethyl) adamantyl; C1-C4 alkyl (C5-C10 cycloalkyl) such as 2-methylcyclopentyl, 3-ethylcyclopentyl, 2-methylcyclohexyl, 3-methylcyclohexyl, -propylcyclohexyl, 2-methyladamantyl or 3-methyladamantyl; or (C 5 -C 10) cycloalkyl (C 5 -C 10) cycloalkyl, such as 3-cyclohexylcyclopentyl or 4-cyclohexylcyclohexyl.

Of the aryl groups substituted with 1-3 substituents B or C, halogen (C 6-10 aryl) groups such as 2-fluorophenyl, 3-bromophenyl, 4-fluorophenyl,

3,4-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3, 4-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,4,5-tribromophenyl or 2-fluoronaphthyl; C 1-4 alkoxy (C 6-10 aryl) such as 2-ethoxyphenyl,

3-propoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2,4-dimethoxyphenyl, 2,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl - or 2-methoxynaphthyl; C2 -C5 alkoxycarbonyl-C6-C10 aryl groups such as 2- (methoxycarbonyl) phenyl, 4- (ethoxycarbonyl) phenyl, 2- (methoxy) carbonyl) naphthyl group; nitro (C 6 -C 10 aryl) groups such as 2-nitrophenyl, 3-nitrophenyl, 4-nitrophenyl; cyano (C 6 -C 10 aryl) groups such as 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl; benzoyl (C 6 -C 10 aryl) groups such as 2-benzoylphenyl, 3-benzoylphenyl, 4-benzoylphenyl, 2-benzoylnaphthyl; halogen (C 1 -C 4 alkyl) (C 6 -C 10 aryl) groups such as 2-trifluoromethylphenyl, 3-trichloromethylphenyl, 4- (trifluoromethyl) methyl) phenyl, 2,4-di (trifluoromethyl) phenyl, 2,5-di (trifluoromethyl) phenyl, 3,4,5-tris (trifluoromethyl) phenyl, or 2- (trifluoromethyl) naphthyl; C1-C4-alkyl, C6-C10-aryl, such as 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl; , 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2-ethylphenyl, 3-propylphenyl, 4-butylphenyl, 3,4-diethylphenyl, 2 4-diethylphenyl, 2,5-dipropylphenyl, 3,4,5-trimethylphenyl or 2-methylnaphthyl; or (C 5 -C 10 cycloalkyl) - (C 6 -C 10 aryl) groups such as 4-cyclohexylphenyl.

• · • **·«· · · • ····· ·· · ··· · · · ··· ·«

Of the aralkyl groups substituted with 1-3 substituents B or C, halo (C 7 -C 12 aralkyl) groups such as 2-fluorobenzyl, 3-bromophenethyl, 4-fluorobenzyl, are preferred. 3,4-difluorobenzyl, 2,4-difluorobenzyl,

2.5-difluorobenzyl, 2-chlorophenethyl, 3-chlorobenzyl, 4-chlorobenzyl, 4-bromobenzyl, 4-chlorophenethyl, 3,4-dichlorobenzyl, , 2,4-dichlorobenzyl, bis (2,4-dichlorophenyl) methyl,

2,5-dichlorobenzyl, 3,4,5-tribromobenzyl or 2-fluoronaphthylmethyl; C 1-4 alkoxy (C 7-12 aralkyl) groups such as 2-ethoxyphenethyl, 3-propoxybenzyl, 4-methoxybenzyl, 4-methoxyphenyldiphenyl; methyl, 3,4-dimethoxyphenethyl, 2,4-dimethoxybenzyl, 2,5-dimethoxybenzyl, 3,4,5-trimethoxyphenethyl or 2-methoxynaphthylmethyl; C2-C5 alkoxycarbonyl (C7-C12 aralkyl) groups such as 2- (methoxycarbonyl) phenethyl, 4- (ethoxycarbonyl) benzyl or 2- (methoxy) carbonyl) -naphthyl-methyl; nitro (C 7 -C 12 aralkyl) groups such as 2-nitrobenzyl, 3-nitrophenethyl, 4-nitrobenzyl, bis (2-nitrophenyl) methyl; cyano (C7-C12 aralkyl) groups such as 2-cyanophenethyl, 3-cyanobenzyl, 4-cyanobenzyl, 4-cyanophenethyl or 4-cyanobenzyldiphenyl methyl; benzoyl (C7-C12 aralkyl) groups such as 2-benzoylphenethyl, 3-benzoylbenzyl, 4-benzoylbenzyl or 2-benzoylnaphthylmethyl; halogen (C 1 -C 4 alkyl) (C 7 -C 12 aralkyl) groups such as 2- (trifluoromethyl) benzyl, 3- (trichloromethyl) phenethyl, 4- (trifluoromethyl) phenyl; methyl) benzyl, 2,4-di- (trifluoromethyl) benzyl, 2,5-di (trifluoromethyl) phenethyl,

3.4.5-tris (trifluoromethyl) benzyl or 2- (trifluoromethyl) naphthylmethyl; C1-C4 alkyl (C7-C12 aralkyl) groups such as 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-methylphenethyl, , 4-dimethylbenzyl, 2,4-dimethylphenethyl, 3,4-dimethylbenzyl, 2,4-dimethylphenethyl, 2,5-dimethylbenzyl, 2-ethylphenethyl- , 3-propylphenethyl, 4-butylbenzyl, 3,4-diethylbenzyl, 2,4-diethylphenethyl, 2,5-dipropylbenzyl, 3,4,5-trimethyl- benzyl,

2.4.6-trimethylbenzyl or 2-methylnaphthyl; or (C 5 -C 10 cycloalkyl) - (C 7 -C 12 aralkyl) groups such as 4-cyclohexylbenzyl.

Preferred examples of heterocyclic groups substituted with 1-3 B or C are halogen substituted heterocyclic groups such as 3-fluoro-tetrahydrobenzothiophen-2-yl, 3-bromo-piperidin-4-yl, 2-fluoro-quinolin-3 -yl, 3-fluoro-morpholin-2-yl, 3-fluoro-piperazin-2-yl, 2-chloro-piperidin-4-yl, 3-chloro-tetrahydro-benzothiophen-2-yl,

4-chloropiperidin-2-yl or 2,6-dichloropiperidin-4-yl; heterocyclic groups substituted with C 1-4 alkoxy groups such as 3-ethoxymorpholin-2-yl, 4-methoxyquinolin-8-yl, 2,6-dimethoxypiperidin-4-yl; heterocyclic groups substituted with C2-C5 alkoxycarbonyl groups such as 3- (methoxycarbonyl) tetrahydro-benzothiophen-2-yl or 4- (ethoxycarbonyl) -tetrahydrobenzothiophen-2-yl; cyano-substituted heterocyclic groups such as 3-cyanopyridin-2-yl, 3-cyano;

-tetrahydrobenzothiophen-2-yl or 3-cyano-piperazin-2-yl; benzoyl-substituted heterocyclic groups such as 2-benzoylpiperidin-4-yl or 4-benzoylpyridin-2-yl; halo-substituted heterocyclic groups such as 2- (trifluoromethyl) quinolin-3-yl, 3-trichloromethylmethyl-morpholin-2-yl, 4- ( trifluoromethyl) tetrahydrobenzothiophen-2-yl or 2,6-di (trifluoromethyl) piperidin-4-yl; heterocyclic groups substituted with C 1 -C 4 alkyl groups such as 3-methyl-tetrahydro-benzothiophen-2-yl, 4-methyl-tetrahydrobenzothiophen-2-yl, 4-methyl-piperidin-2-yl or 2,6-dimethyl-pyridine -4-yl, 2,5-dimethylpyridin-4-yl; or heterocyclic groups substituted with C 5 -C 10 cycloalkyl, such as 4-cyclohexylpiperidin-2-yl.

The compounds of formula (I) of the present invention may also exist in the form of salts. Preferred are salts with inorganic acids such as hydrogen halide salts such as hydrofluoride, hydrochloride, hydrobromide or hydroiodide or other inorganic acids such as nitrate, perchlorate, sulfate or phosphate; organic acid salts such as alkanesulfonate salts, especially alkanesulfonic acid salts having from 1 to 3 carbon atoms in the alkane moiety and optionally having from 0 to 5 halogen substituents, such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, trifluoroethanesulfonate, pentafluoro especially with the alkyl group where appropriate.

saturated arylsulfonates containing from 0 to 3 alkyl groups, each containing from 1 to 3 carbon atoms, such as the benzenesulfonate or p-toluenesulfonate salt or other organic acid salts such as fumarate, succinate, citrate, tartrate, oxalate; or maleate salts; salts of amino acids such as glutamate or aspartate salts. Preferred are the onium salts formed when a substituent A is attached to a tertiary nitrogen atom, i.e., the fourth substituent on a nitrogen atom that is saturated and the R3 a heterocyclic group attachment site. Pharmaceutically acceptable salts are also part of the invention.

The compounds of the invention may also exist in optically active form. If there is an asymmetric carbon atom in the molecule, stereoisomers of R configuration and S configuration are possible. If m is 1 or 2, geometric isomers can also be formed. The present invention includes each isomer and mixture of isomers.

Preferred are compounds of formula I wherein:

(1) R1 nitro, amino or protected amino;

(2) R1 an amino group or a protected amino group;

(3) R1 a protected amino group;

(4) R2 amino, protected amino or hydroxy;

(5) R2 an amino group or a protected amino group;

(6) R3 1-2 of Group A as defined above

• · · • · · ·

- an amino group or a heterocyclic group substituted with 26 substituents attached through the ring nitrogen atom;

(7) R3 1-2 amino groups or heterocyclic groups substituted by a substituent on group A 'which are attached via the ring nitrogen atom;

(8) R3 1-2 amino groups or heterocyclic groups substituted by a substituent of group A which are attached via the ring nitrogen;

(9) m is 0 or 1; and (10) n is an integer from 2 to 6;

wherein the substituents in Group A 'are linear or branched C 1 -C 4 alkyl groups, C 5 -C 10 optionally bridged ring hydrocarbyl groups, C 6 -C 10 aromatic ring hydrocarbyl groups optionally fused to cycloalkyl and optionally 1-2 B or Substituted with a group C substituent, a heterocyclic group, and a 1-2 group B or C substituted heterocyclic group, and group A substituents: straight or branched C 1 -C 4 alkyl groups, adamantylated, phenyl, and phenyl substituted with 1 to 2 halogens and / or linear or branched C 1 -C 4 alkyl groups.

Representative, non-limiting compounds of formula (I) of the present invention are listed in the following Table, where the following abbreviations are used:

» « ♦ · · · ··· · · · · · · • ···<· 4 ·· • ····· · · · ··· ·· · ··· ··

<td>Ac</td><td>acetyl</td>

<td>Ada</td><td>adamantyl</td>

<td>MCTB</td><td>3- (methoxycarbonyl) -tetrahidrobenzotienil</td>

<td>TFAC</td><td>trifluoroacetyl</td>

<td>et</td><td>ethyl</td>

<td>Moorish</td><td>morpholinyl</td>

<td>Pipe</td><td>piperidino</td>

<td>Bu</td><td>isobutyl</td>

<td>pr</td><td>propyl</td>

<td>Bu</td><td>butyl</td>

<td>Me</td><td>methyl</td>

<td>Ph</td><td>phenyl</td>

<td>Quin</td><td>quinoline</td>

<td>Ind</td><td>indanylmethoxy</td>

» ·

<td>Number of compound</td><td>R1</td><td>R2</td><td>R3 m</td><td colspan="2">n</td>

··

• · « ··

<td> 43</td><td>4 TFAcO-</td><td>3 ΝΟ2-</td><td>1-Ada-NH-</td><td> 1</td><td> 0</td>

<td> 44</td><td>3 TFAcO-</td><td>4 ΝΟ2-</td><td>1-Ada-NH-</td><td> 1</td><td> 0</td>

<td> 51</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>2,4-dÍMePh-NH</td><td> 1</td><td> 1</td>

<td> 59</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>2,4-diMePh-NH-</td><td> 2</td><td> 4</td>

<td> 64</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>2,4-diMePh-NH-</td><td> 0</td><td> 3</td>

• · · · · • *♦· · · · · · · · ··· ·· 4

- 3ο -

<td> 67</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>2,4-diMePh-NH-</td><td> 1</td><td> 1</td>

<td> 74</td><td>4 TFAcO-</td><td>3 ΝΟ2-</td><td>(Et)2N-</td><td> 1</td><td> 0</td>

<td> 75</td><td>3 TFAcO-</td><td>4 ΝΟ2-</td><td>(Et)2N-</td><td> 1</td><td> 0</td>

<td> 76</td><td>4 AcO-</td><td>3 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 77</td><td>4 ΗΟ-</td><td>3 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 78</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>1-morpholine</td><td> 0</td><td> 2</td>

<td> 79</td><td>4 ΗΟ-</td><td></td><td>1-morpholine</td><td> 0</td><td> 3</td>

<td> 81</td><td>4 ΗΟ-</td><td>3 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 82</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 1</td>

<td> 83</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 2</td>

<td> 84</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 3</td>

<td> 85</td><td>4 ΗΟ-</td><td>3 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 4</td>

<td> 86</td><td>3 AcO-</td><td>4 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 87</td><td>3 ΗΟ-</td><td>4 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 89</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 0</td><td> 3</td>

<td> 90</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 0</td><td> .4</td>

<td> 91</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 92</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 1</td>

<td> 94</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 1</td><td> 3</td>

<td> 95</td><td>3 ΗΟ-</td><td>4 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 4</td>

<td> 96</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 2</td><td> 0</td>

<td> 97</td><td>3 ΗΟ-</td><td>4 ΝΗ2-</td><td>1-morpholine</td><td> 2</td><td> 1</td>

<td> 98</td><td>3 ΗΟ-</td><td>4 ΝΟ2-</td><td>1-morpholine</td><td> 2</td><td> 2</td>

<td> 100</td><td>3 ΗΟ-</td><td>4 ΝΉ2-</td><td>1-morpholine</td><td> 2</td><td> 4</td>

<td> 101</td><td>4 TFAcO-</td><td>3 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 102</td><td>3 TFAcO-</td><td>4 ΝΟ2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

• · · ··· · • · • ··

- 32 • · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

<td> 140</td><td>4 -TFAcO -</td><td>3-NO2-</td><td>iBu-NH-1</td><td> 0</td>

<td> 141</td><td>3 TFAcO-</td><td>4-NO2-</td><td>iBu-NH-1</td><td> 0</td>

<td> 167</td><td>3-HO</td><td>4-NH2-</td><td>2,4-diClPh-NH-1</td><td> 3</td>

<td> 168</td><td>3-HO</td><td>4-NO2-</td><td>2,4-diCIPh-NH-1</td><td> 4</td>

<td> 170</td><td>3-HO</td><td>4-NH2-</td><td>2,4-diCIPh-NH-1</td><td> 6</td>

<td> 172</td><td>3-HO</td><td>4-NH2-</td><td>2,4-diClPh-NH-2</td><td> 1</td>

<td> 173</td><td>3-HO</td><td>4-NO2-</td><td>2,4-diCIPh-NH-2</td><td> 2</td>

• · «e ·· · · · · · · ··································································································· · · · ·

<td> 175</td><td>3 ΗΟ-</td><td>4-NH2-</td><td>2,4-diClPh-NH-</td><td> 2</td><td> 4</td>

<td> 178</td><td>4 TFAcO-</td><td>3-NO2-</td><td>(Ph)2N-</td><td> 1</td><td> 0</td>

<td> 179</td><td>3 TFAcO-</td><td>4-NO2-</td><td>(Ph)2N-</td><td> 1</td><td> 0</td>

<td> 196</td><td>3-NH-TFAC</td><td>4-NO2-</td><td>1-morpholine</td><td> 1</td><td> 0</td>

<td> 204</td><td>4-NH2-</td><td>3-NH2-</td><td>1-morpholine</td><td> 1</td><td> 1</td>

·♦ «

·*

<td> 213</td><td>4-NH-TFAC</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 0</td>

<td> 214</td><td>3-NH-TFAC</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 0</td>

<td> 215</td><td>4 ΝΗ2-</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 0</td>

<td> 216</td><td>3 ΝΗ2-</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 0</td>

<td> 217</td><td>4 ΝΗ2-</td><td>3 ΝΗ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 0</td>

<td> 218</td><td>4-NH-TFAC</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 1</td>

<td> 219</td><td>3-NH-TFAC</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 1</td>

<td> 220</td><td>4 ΝΗ2-</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 1</td>

<td> 221</td><td>3 ΝΗ2-</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 1</td>

<td> 222</td><td>4 ΝΗ2-</td><td>3 ΝΗ2-</td><td>2,4-diClPh-NH-</td><td> 1</td><td> 1</td>

<td> 223</td><td>4-NH-TFAC</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 2</td>

<td> 224</td><td>3-NH-TFAC</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 2</td>

<td> 225</td><td>4 ΝΗ2-</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 2</td>

<td> 226</td><td>3 ΝΗ2-</td><td>4 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 2</td>

<td> 227</td><td>4 ΝΗ2-</td><td>3 ΝΗ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 2</td>

<td> 228</td><td>4-NH-TFAC</td><td> 3-ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 3</td>

<td> 229</td><td>4 ΝΗ2-</td><td>3 ΝΟ2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 3</td>

<td> 230</td><td>4 ΝΗ2-</td><td> 3-^2-</td><td>2,4-diClPh-NH-</td><td> 0</td><td> 3</td>

<td> 231</td><td>4-NH-TFAC</td><td>3 ΝΟ2-</td><td>2,5-diMePh-NH-</td><td> 0</td><td> 2</td>

<td> 232</td><td>4 ΝΗ2-</td><td>3 ΝΟ2-</td><td>2,5-diMePh-NH-</td><td> 0</td><td> 2</td>

<td> 233</td><td>4 ΝΗ2-</td><td>3 ΝΗ2-</td><td>2,5-diMePh-NH-</td><td> 0</td><td> 2</td>

• ·♦ · · ·· •· · · · ·· · · • ··· · « · ·· • · ···· · · · ··· ·· · ··· ··

<td></td><td colspan="2">These compounds are:</td><td>are preferred</td><td></td><td></td>

<td> 230,</td><td> 236, 239, 247,</td><td>250, 25B</td><td colspan="3">and 260 numbers</td>

<td>salts</td><td> •</td><td></td><td></td><td></td><td></td>

and their salts are even more preferred.

Most preferred are 4, 54, 5, 25, 29, 79, 91, 184, 189

36 194, 212, 227, 230, 236, 239, 247, 250, 256 and 260 and their salts, in particular compounds 250, 251, 256, 257, 260 and 261.

NGF promoter effect

Furukawa et al. Have reported that fibroblast-forming LM cells derived from murine connective tissue are capable of producing and secreting relatively large amounts of NGF and that catecholamines accelerate such production and secretion of NGF (J. Bioi. Chem. 261. 6039- 6047, 1986). Following the assay method of Furukawa, but using the compounds of the invention and the epinephrine, isoproterenol, L-DOPA, known as NGF promoter, and coffee acid, the effects of NGF production and secretion were investigated. The compounds of the invention were used at 10 gamma / ml and the known compounds at 20 gamma / ml.

LM cells were cultured in Medium 199 containing 0.5% peptone [see Med. See, for example, Morgan et al., Proc. Soc Exp Bioi. Med., 73, 1 (1950) or Morgan et al., J. Natl. Cancer Inst., 16, 557 (1955)]. For each well of a 24-well culture plate, approx. 5x104 LM cells were placed in a CO2 incubator (37 ° C, 5% CO 2)2) were grown to confluence. After removal of the medium, the cultured cells were washed once with washing solution # 199 medium containing 0.5% bovine serum albumin (Fraction V, Sigma). The test compounds were added at a specified concentration to Medium 199 containing 0.5% bovine serum albumin and used to treat 0.5 ml of LM cells. After the LM cells were CO2 cultured in an incubator, medium was separated and NGF levels were measured.

An enzyme immunoassay was used to quantify NGF [Korshing, Thoenen et al., Proc. Natl. Acad. Sci. USA 80: 3513-3516 (1983). 75 microliters of anti-mouse beta-NGF antibody solution (0.3 microgram / ml, pH 9.6; Boehringer Mannheim) was pipetted into each well of a 96-well polystyrene plate. After allowing the plate to stand for one hour at room temperature, the antibody was removed by washing three times with wash solution. 50 microliters of standard beta-NGF solution (Wako Pure Chemical Industries Ltd.) or 50 microliters of separated medium were pipetted into the wells. The plate was allowed to stand at room temperature for 68 hours, then the standard beta-NGF solution or test solution was removed and each well was washed three times. 50 microliters of a solution of beta-galactosidase-labeled beta-NGF monoclonal antibody (100 mU / ml, pH 7.0; Boehringer Mannheim) was pipetted into each well. After standing for 15-18 hours at 4 ° C, the enzyme-labeled antibody was removed and the wells were washed three times with 100 microliters of chlorophenyl red-beta-D-galactopyranoside solution (1 mg / ml). pH 7.3; Boehringer Mannheim). The color was allowed to develop for 2-3 hours at room temperature and the absorbance was measured at 570 nm.

The amount of NGF was calculated from a standard curve.

- 38 The results are expressed as the relative value (%) which is

<td>produced by cells</td><td>and how much NGF selected</td>

<td colspan="2">which were not treated in the test sample.</td>

<td>gyületekkel. The numerical values</td><td>(control%) three controls</td>

<td colspan="2">average (without addition of test compound)</td>

<td>as sulfur.</td><td></td>

<td>Known veins</td><td>% control</td>

<td>epinephrine</td><td> 140 + 24</td>

<td>isoproterenol</td><td> 168 + 22</td>

<td>caffeic acid</td><td> 123 + 14</td>

Compound of the Invention Control%

<td> 22.</td><td>example</td><td>of</td><td>compound</td><td> 380</td>

<td> 34.</td><td>example</td><td>of</td><td>compound</td><td> 606</td>

<td> 40.</td><td>example</td><td>of</td><td>compound</td><td> 276</td>

<td> 43 .</td><td>example</td><td>of</td><td>compound</td><td> 491</td>

<td> 53 .</td><td>Nelda</td><td>of</td><td>veqvület</td><td> 315</td>

It will be appreciated that the phenyl derivatives of the present invention include those which exhibit excellent NGF production and secretion promoting activity. They also have low toxicity. The active derivatives are thus useful in the treatment of dementia, cerebral ischemia and various neural dysfunctions.

Therefore, the present invention also provides pharmaceutical compositions which are compounds of formula I, except for R1 intermediates containing a nitro group, and pharmaceutically acceptable carriers.

The compounds of the formula I according to the invention may be administered orally, in the form of tablets, capsules, granules or syrups and parenterally, in the form of injections and suppositories. The pharmaceutical compositions may be prepared using conventional excipients such as carriers, binders, disintegrants, lubricants, stabilizers, or modifiers by conventional means. Dosages may vary depending on the symptoms and the age of the patient, but generally 0.1 to 1000 mg / kg / day, preferably 1 to 100 mg / kg / day, may be administered to an adult once or more divided daily.

The compounds of formula (I) of the present invention may be prepared by the process of the invention, which comprises reacting a reactive carboxylic acid derivative of formula (II) with a compound of formula (III) and1) to form an amide of formula (A) wherein R1 is a nitro group, 1 or 2 amino substituted with a group A as defined in claim 1 or a protected amino group; R 2 'is an amino group substituted with 1 or 2 group A substituents as defined in claim 1: a protected amino group as defined in claim 1; A substituted hydroxy group or a protected hydroxy group as defined in claim 1; Y is leaving group and R3, m and n are as defined above), and if necessary or desired, the product is converted to another compound of the invention, for example by:

(1) when R 1 'is a nitro group, it is reductively converted to a compound of formula (I) wherein1 and (3) deprotecting the amino group, (2) when R 1 'is a protected amino group, and / or (3) deprotecting the R 2' protected amino group or protected hydroxy group.

The process involves the reaction of a reactive carboxylic acid derivative of formula (II) with a compound of formula (III). The reaction is preferably carried out in an inert solvent in the presence of a base to form the compound of formula (I ') and HY.

The nature of the Y leaving group is not critical, so that Y is a suitable leaving group commonly used in the nucleophilic reaction of amide formation. Typically, the leaving group Y is a halogen atom such as chlorine, bromine or iodine; C 1 -C 6 alkanesulfonyloxy groups such as methanesulfonyloxy or ethanesulfonyloxy; a haloalkanesulfonyloxy group in which the alkane moiety has from 1 to 3 carbon atoms and the number of halogen substituents from 1 to 6, such as trifluoromethanesulfonyloxy or pentafluoroethane sulfonyloxy; or an arylsulfonyloxy group optionally substituted with 1 to 3 alkyl groups and each alkyl group having 1 to 3 carbon atoms, such as benzenesulfonyloxy or p-toluenesulfonyloxy. Preferably, Y is halogen.

There is no particular restriction on the inert solvent provided that it does not interfere with the reaction and dissolves the starting materials to some extent. Preferred solvents include aromatic hydrocarbons such as benzene, toluene or xylene; halogenated hydrocarbons such as methylene chloride or chloroform; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran or dioxane.

There are no restrictions on the base, provided that it is effective in such a reaction. Examples of preferred bases include organic bases such as triethylamine, tributylamine, diisopropylethylamine, N-methylmorpholine, pyridine, 4- (Ν, Ν-dimethylamino) pyridine, Ν, Ν-dimethyl-. aniline, N, N-diethylaniline, 1,5-diazabicyclo [4.3.0] nona-5-ene, 1,4-diazabicyclo [2.2.2] octane (DABCO) or 1,8-diazabicyclo [5.4.0 ] undec-7 (DBU).

A quaternary ammonium salt such as benzyltriethylammonium chloride or tetrabutylammonium chloride or a crown ether such as dibenzyl-18-crown-6 may be added to facilitate the completion of the amide formation reaction.

The reaction is preferably carried out at a temperature of -10 ° C to 50 ° C, more preferably 0 ° C to 30 ° C, and generally takes from 1 to 3 hours, although the time depends on various factors such as reaction temperature, starting materials, reagents and varies depending on the inert solvent.

After completion of the amide formation reaction, the compound of formula (I *) of the present invention may be isolated from the reaction mixture by conventional means. For example, • ♦ · ·

The reaction mixture is suitably neutralized and, after filtering off the insoluble material, a water immiscible solvent is added. The solvent extract was then separated, washed with water, and the solvent removed by distillation to give the target compound. If necessary, the target compound can be further purified by conventional means such as recrystallization, reprecipitation and / or chromatography.

If desired, one or more of the conversions that can be performed can be performed. The order is not critical and removal of the various protecting groups can be accomplished simultaneously. It is not necessary to isolate the amide reaction product prior to the conversion.

The first step, if desired, of converting the nitro group into an amino group can be accomplished by known methods for converting the nitro group into an amino group. Suitable reduction methods include:

(a) Reactions with metals such as sodium amalgam or transition metals such as tin, zinc, iron, titanium trichloride or tin dichloride. Suitable solvent systems are aqueous methanol, aqueous acetone, aqueous tetrahydrofuran, usually with hydrochloric acid, and optionally ammonium chloride. An example of such a solvent system is ammonium chloride / water - methanol or water - hydrochloric acid - acetone;

(b) hydrides such as alkali metal borohydride such as sodium borohydride or lithium borohydride; an aluminum hydride such as lithium aluminum hydride or lithium triethoxyaluminum hydride; or with another hydride reagent, *

43, for example, sodium tellurium hydride, ether such as diethyl ether or tetrahydrofuran, or a mixture thereof. When sodium borohydride or sodium tellurium hydride is used as a reducing agent, in addition to the above, alcohol such as methanol or ethanol may also serve as a solvent;

(c) catalytic reduction at room temperature in the presence of catalysts such as palladium carbon, platinum or Raney nickel in an alcohol such as methanol or ethanol, in an ether such as tetrahydrofuran or dioxane, in a fatty acid such as acetic acid or in water;

(d) reactions with Lewis acids such as aluminum chloride, tin tetrachloride or titanium tetrachloride and a hydrogenated silyl compound such as hydrotriethylsilane or hydrotriphenylsilane; or (e) reduction with a radical reducing agent such as hydrotributyltin, hydrotriphenyltin or hydrodibutyltin and a radical reducing agent such as azobisisobutyronitrile or triphenylboron.

Of these methods, conventional catalytic reduction according to process (c) is preferred.

The optional conversion (2), when the amino protecting group is removed, and which is part of the optional conversion (3), can be carried out according to conventional methods, which will vary depending on the nature of the actual protecting group.

When the amino protecting group is a silicon group, it may be removed by treatment with a fluoride anion release compound such as tetrabutylammonium fluoride. The treatment is usually carried out in a solvent. There are no particular restrictions on the choice of solvent, as long as it does not affect the reaction. There are no limitations on the reaction temperature and reaction time, and the silyl protecting group is generally removed at room temperature using a reaction time of 10-18 hours.

When the amino protecting group is an aliphatic acyl group, an aromatic acyl group, an alkoxycarbonyl group, or a substituted methylene group forming a Schiff base, removal may be accomplished by treatment with an acid or base in the presence of an aqueous solvent. When an acid is used, there are no particular restrictions on the acid, preferably an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid or hydrobromic acid. When a base is used, there are no particular restrictions on the choice of base, provided that the base does not react with the rest of the compound, preferably an alkali metal alkoxide such as sodium methoxide; an alkali metal carbonate such as sodium carbonate or potassium carbonate; an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide; or ammonia such as aqueous ammonia solution or concentrated methanolic ammonia. There is no limitation on the solvent, typically solvents commonly used in hydrolytic reactions such as water; organic solvents such as alcohol, such as methanol, ethanol, ethanol,

a woman or propanol or an ether such as tetrahydrofuran or dioxane; or a mixture of water and an organic solvent. The appropriate reaction temperature will vary depending upon the starting materials and the acid or base employed and is not particularly limited in its choice. To minimize side reactions, deprotection is carried out at a temperature of 0 ° C to 150 ° C for 1 to 10 hours.

When the amino protecting group is an aralkyl group or an aralkyloxycarbonyl group, a method may be employed.

in a solvent, numerous deprotections

In general, a reducing agent, preferably a catalytic reduction using a catalyst at room temperature or treatment with an oxidizing agent, an alkali metal or a halogen, removes the above protecting groups.

For the removal of the protecting group by catalytic reduction, the choice of solvent is not particularly limited provided that it is not involved in the reaction and the solvent is preferably an alcohol such as methanol, ethanol or isopropanol; an ether such as diethyl ether, tetrahydrofuran or dioxane; an aromatic hydrocarbon such as toluene, benzene or xylene; an aliphatic hydrocarbon such as hexane or cyclohexane; an ester such as ethyl acetate or propyl acetate; fatty acids such as acetic acid; or a mixture of the above solvents and water. There are no particular restrictions on the catalyst, such as palladium on carbon, Raney nickel, platinum oxide, platinum carbon black, rhodium aluminum oxide, triphenylphosphine rhodium chloride, or palladium on barium sulfate, which are commonly used for catalytic reduction. The pressure is not particularly limited in the reduction, and is usually from 1 to 10 atmospheres. The reaction temperature and reaction time may vary depending on the starting materials and the catalyst used, but are usually carried out at a temperature of 0 ° C to 100 ° C and a reaction time of 5 minutes to 24 hours.

There is no particular restriction on the choice of solvent for the oxidative removal of the protecting group, provided that it is not involved in the reaction. Preferred solvents are aqueous organic solvents wherein the organic solvent is a ketone such as acetone; a halogenated hydrocarbon such as methylene chloride, chloroform or carbon tetrachloride; a nitrile such as acetonitrile; an ether such as diethyl ether, tetrahydrofuran or dioxane; an amide such as dimethylformamide, dimethylacetamide or hexamethylphosphoric triamide; or a sulfoxide such as dimethyl sulfoxide. The oxidizing agent commonly used in this type of reaction is, and is not limited to, potassium persulfate, sodium persulfate, cerium ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyano-p-. benzoquinone (DDQ). The reaction temperature and reaction time may vary depending on the starting materials and the oxidizing agents used, but the reaction is usually carried out at a temperature of 0 ° C to 150 ° C and a reaction time of 10 minutes to 24 hours.

The reaction is conveniently carried out with alkali metal or sodium sodium in an alcohol such as methanol or ethanol, preferably at -72 ° to -20 ° C, to remove the protecting group with an alkali metal.

Suitable reagents for deprotection by halide treatment include, for example, aluminum chloride / sodium iodide or an alkylsilyl halide such as trimethylsilyl iodide in a solvent. There are no particular restrictions on the solvent provided that it is not involved in the reaction. A preferred solvent is a nitrile such as acetonitrile, a halogenated hydrocarbon such as methylene chloride or chloroform; or a mixture of these. The reaction temperature and reaction time vary depending on the starting materials, but are usually carried out at a temperature of 0 ° C to 50 ° C and a reaction time of 5 minutes to 3 days.

When the amino protecting group is an alkenyloxycarbonyl group, it is usually removed by treatment with a base to remove an aliphatic acyl group, an aromatic acyl group, an alkoxycarbonyl group, or a Schiff-base substituted methylene group under similar conditions.

When the amino protecting group is allyloxycarbonyl, its removal can be easily accomplished with palladium and triphenylcarbonyl or nickel tetracarbonyl with minimal side reactions.

Depending on the selection of the protecting groups and the conditions for deprotection, the deprotection of the amino group may be accomplished while also deprotecting the hydroxy group, which reaction is optionally carried out in (3).

In the optional conversion (3), the deprotection of the hydroxy group is carried out according to conventional methods, which vary according to the nature of the actual protecting group.

When the hydroxy protecting group is a silyl group, an aralkyl group, an aralkyloxycarbonyl group, an aliphatic acyl group, an aromatic acyl group or an alkoxycarbonyl group or an alkenyloxycarbonyl group, the removal may be carried out using the same methods as those described for the amino protecting group. .

When the hydroxy protecting group is an alkoxymethyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrofuranyl or substituted ethyl group, its removal is usually accomplished by treatment with an acid in a solvent. There are no restrictions on the acid, preferably Bronsted acid, an inorganic acid such as hydrochloric or sulfuric acid, an organic acid such as acetic acid or p-toluenesulfonic acid or a strongly acidic cation exchange resin such as Dowex 50W. There are no particular restrictions on the choice of solvent, provided that it is not involved in the reaction. A preferred solvent is an alcohol such as methanol or ethanol; an ether such as tetrahydrofuran or dioxane; or a mixture thereof with water. The reaction temperature and reaction time may vary depending on the starting materials and the acid chosen, but are usually carried out at a temperature of 0 ° C to 50 ° C and a reaction time of 10 minutes to 18 hours.

Depending on the choice of the protecting groups and the reaction conditions used for their removal, it can be achieved that the deprotection of the protected hydroxy group also results in the deprotection of the protected amino group, these reactions being between optional (2) and optional (3) conversions.

After one or more optional conversions have been made, the desired compound of formula (I) of the present invention is isolated from the reaction mixture in a conventional manner. For example, a water immiscible solvent is added to give a solvent extract which can be washed with water and then removed by distillation to give the target compound. If necessary, the target compound can be further purified by known methods such as recrystallization by reprecipitation and / or chromatography.

The reactive carboxylic acid derivative of formula (II) required as starting material for the process of the invention may be prepared from the appropriate acid, for example by halogenation. Such halogenation is generally accomplished using conventional halogenating agents. Preferred halogenating agents are thionyl halides such as thionyl chloride, thionyl bromide or thionyl iodide; sulfuryl halides such as sulfuryl chloride, sulfuryl bromide or sulfuryl iodide; phosphorus trihalides such as phosphorus trichloride, phosphorus tribromide or phosphorus triiodide; phosphorus pentahalides such as phosphorus pentachloride, phosphorus pentabromide or phosphorus pentajodide;

phosphorus oxyhalides such as phosphorus oxychloride, phosphorus oxybromide or phosphorus oxy iodide. Phosphorus oxyhalide is a particularly preferred halogenating agent.

The starting acid itself is a known compound or can be readily prepared by known methods. A carboxylic acid such as 3-nitro-4-aminocinnamic acid containing a nitro and an amino group substituent, for example, as described in Annalene Chimica 48, 958-991 (1958) or Chem. Bér.16, 2042. synthesized. A carboxylic acid such as 3-nitro-4-hydroxy-cinnamic acid having a nitro and a hydroxy substituent, such as J. Chem. Soc. 3072 (1952) or J. Am. Chem. Soc., 79, 4114 (1957). Carboxylic acids containing two amino substituents or one amino and one hydroxy substituent can be obtained by reduction of the corresponding nitro derivatives.

The increased carboxylic acids can be obtained by analogous methods or by methods based on carbon chain extension. For example, a known amino-cinnamic acid or hydroxy-cinnamic acid is protected on its amino or hydroxy group, the chain extension reaction is carried out, the product is nitrated, then the protecting group is removed and, if desired, the nitro substituent is reduced.

Various methods are known for increasing the carbon number of a carboxylic acid. In general, the starting carboxylic acid is reduced to the corresponding alcohol and then the hydroxy group is activated, i.e., an leaving group such as chlorine, bromine or iodine; an alkanesulfonyloxy group such as methanesulfonyloxy or ethanesulfonyloxy group, a haloalkanesulfonyloxy group such as trifluoromethanesulfonyloxy or pentafluoroethanesulfonyloxy group or an arylsulfonyloxy group such as converting the toluenesulfonyloxy group and then activating the carbon chain of the compound so activated with one or two carbon atoms using one of the following procedures, generally at a temperature of from -78 ° C to 50 ° C, lengthens.

The carbon chain of the activated compound is one carbon atom (1) using 1,3-dicyano;

(2) using metal cyanide;

(3) After preparation of the Grignard reagent, it may be prolonged by reaction with carbon dioxide.

To extend the carbon chain by two carbon atoms, (1) a malonic acid derivative may be used;

(2) acidically hydrolyzing an acetic acid derivative.

The 1,3-dicyano method can be carried out by reacting the 1,3-dicyano with an organic or inorganic base such as sodium hydride, potassium methoxide, potassium hydroxide or lithium diisopropyl nitride in an ether such as diethyl ether. , diisopropyl ether, tetrahydrofuran or dioxane, in an inert gas atmosphere, such as nitrogen, to give the metal salt which is then reacted with the activated compound and then the product with a strong acid, for example, hydrolysis with hydrochloric acid.

• * • · · · · • ··· · • · · ·· · ♦ · ·

52 In the metal cyanide process, the metal cyanide is reacted with the activated compound to form the corresponding cyano compound which is then hydrolyzed in the usual manner.

The carbon dioxide reaction after the preparation of the Grignard reagent is accomplished by making the activated compound a Grignard reagent by a conventional method and reacting it with carbon dioxide according to known procedures.

The method using the malonic acid derivative involves converting a malonic acid derivative into a metal salt with a metal base in an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran or dioxane, and then reacting with the activated compound and decarboxylating the product. The metal base is selected according to the pKa of the malonic acid derivative, but generally an inorganic base such as an alkali metal carbonate such as sodium carbonate or potassium carbonate; an alkali metal hydride such as lithium hydride, sodium hydride or potassium hydride; an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or barium hydroxide; an organic metal base such as an alkali metal alkoxide such as sodium methoxide or sodium ethoxide; butyl lithium or lithium diisopropylamide.

The acidolytic method employing the acetic acid derivative is carried out by reacting an acetic acid derivative with one of the metal bases mentioned in the malonic acid method in an ether such as diethyl ether, diisopropyl ether, tetrahydrofuran or dioxane, such as in the methylene moiety.

····

53 metal salts are formed which are reacted with the activated compound under standard conditions and then hydrolyzed with an acid.

The Wittig reaction can also be used, which represents a general method for extending the carbon chain of a carboxylic acid by any desired number of carbon atoms. This method yields a carboxylic acid which contains a double bond at the desired site or can be removed by reduction. The Wittig reaction is conveniently carried out by reaction of a Wittig reagent with an aldehyde and, if desired, reduction of the double bond in the resulting product according to conventional procedures.

By properly combining such reactions, a carboxylic acid of the desired chain length and degree of unsaturation can be obtained.

The nitration of the carboxylic acid to introduce the nitro group is conveniently accomplished by conventional methods. For example, nitrate compounds capable of introducing a nitro group can be used, such as fuming nitric acid at room temperature to 50 ° C in an acidic solvent such as a mixture of acetic acid and acetic anhydride.

The following examples illustrate the preparation of the compounds of the invention from known starting materials or by synthesis in a manner known per se. Reference Examples illustrate the preparation of some starting compounds. The description also includes a formulation example.

First Example

N- (1-Adamantyl) -4-acetoxy-3-nitro-cinnamic acid Ig, 4-acetoxy-3-nitro-cinnamic acid prepared in Reference Example 2, was dissolved in 30 mL of methylene chloride. A drop of dimethylformamide was added to the solution and the mixture was cooled to 0 ° C. Oxalyl chloride (3 g) was added, which was then warmed to room temperature and stirred for 2 hours. After 2 hours, the solution was evaporated to dryness under reduced pressure. The residue was dissolved in methylene chloride (20 mL), 1-adamantylamine (0.6 g) and triethylamine (0.4 g) were added and the mixture was stirred for 3 hours. The reaction mixture was diluted with ethyl acetate and washed with water, dilute aqueous sodium hydrogencarbonate solution and saturated aqueous sodium chloride solution, respectively. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed by distillation under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate / n-hexane = 1: 1) to give 1.2 g of the title compound, m.p. 179-180 ° C.

Second Example

N- (1-Adamantyl) -4-hydroxy-3-nitrocinnamic acid amide N- (1-adamantyl) -4-acetoxy-3-nitrocinnamic acid amide prepared in Example 1 was dissolved in methanol (30 mL); 30 ml of 4N aqueous sodium hydroxide solution are added to the solution and the resulting mixture is stirred for 3 hours at room temperature. After 3 hours, methanol under reduced pressure · ··· ····················································

- 55 by distillation. To the residue was added 3N aqueous hydrochloric acid to give the title compound as crystals, m.p. 162-163 ° C.

Third Example

N- (1-Adamantyl) -3- (3-amino-4-hydroxyphenyl) propionamide

Crystals of N- (1-adamantyl) -4-hydroxy-3-nitro-cinnamic acid prepared as described in Example 2 were collected by filtration and dissolved in 30 ml of methanol. To the solution was added 300 mg of 10% palladium on carbon and catalytically reduced it at ambient pressure by bubbling hydrogen for 60 minutes. After 60 minutes, the catalyst was filtered off and the methanol removed by distillation under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate). 0.78 g of the title compound is isolated as a crystalline solid, m.p. 79-80 ° C.

4th Example

N, N-Diethyl-4-acetoxy-3-nitro-cinnamide

The procedure of Example 1 was followed, but using 400 mg of diethylamine to give 950 mg of the title compound as an oily substance.

Rf value: 0.85 (eluent: ethyl acetate).

5th Example

N, N-Diethyl-4-hydroxy-3-nitro-fahéisavamid

Following the procedure of Example 2, however, 900 mg of N, N-diethyl-4-acetoxy-3-nitrophenylacetic acid amide prepared in Example 4 were used to obtain 750 mg of an oily substance.

Rf value: 0.5 (1: 1 v / v ethyl acetate / hexane).

6th Example

N, N-Diethyl-3- (4-hydroxy-3-aminophenyl) propionamide

The procedure of Example 3 was followed, but using 700 mg of N, N-diethyl-4-hydroxy-3-nitro-cinnamic acid prepared in Example 5 to give 550 mg of the title compound, m.p. 92-93 ° C. melted.

7th Example

N, N-Diphenyl-4-acetoxy-3-nitro-cinnamide

The procedure of Example 1 was followed, but using 600 mg of diphenylamine to give 1000 mg of the title compound, m.p. 170-171.5 ° C.

8th Example

N, N-Diphenyl-4-hydroxy-3-nitro-fahéisavamid

Following the procedure of Example 2, however, 950 mg of N, N-diphenyl-4-acetoxy-3-nitro-cinnamic acid amide prepared in Example 7 were used to obtain 700 mg of the title compound, m.p. 197-198 ° C. are good.

9th Example

NN-Diphenyl-3- (4-hydroxy-3-aminophenyl) propionamide

Following the procedure of Example 3, however, 650 mg of N, N-diphenyl-4-hydroxy-3-nitro-cinnamic acid amide prepared in Example 8 were used to obtain 450 mg of the title compound, which was 170.5-171.5. ° C.

10th Example

Ν-Γ 2- (3-Methoxycarbonyl-tetrahydrobenzothienyl) 1-4-acetoxy-3-nitro-cinnamic acid amide

The procedure of Example 1 was followed, but using 800 mg of 2-amino-3-methoxycarbonyltetrahydrobenzothiophene to give 1000 mg of the title compound, mp 184185 ° C.

11th Example

Ν-Γ2- (3-Methoxycarbonyl-tetrahidrobenzotienil) 1-4-hydroxy-3-nitro-cinnamide

In the same manner as in Example 2, 950 mg of N- [2- (3-methoxycarbonyl-tetrahydro-benzothienyl)] - 4-acetoxy-3-nitro-cinnamic acid amide prepared in Example 10 were used, giving 600 mg of the title compound. mp 223-224 ° C.

12th Example

Ν-Γ 4- (Benzyloxy) -3-nitro-cinnamoyl-piperidine

Following the procedure of Example 1, however, 1 g of 4- (benzyloxy) -3-nitro-cinnamic acid and 400 mg of piperidine are reacted to give 0.8 g of the title compound, m.p. 155-156 ° C.

13th Example

N-3- (4-Hydroxy-3-aminophenyl) propionyl-piperidin

0.5 g of N- [4- (benzoyloxy) -3-nitrocinnamoylpiperidine, prepared in Example 12, is dissolved in 30 ml of methanol. To the solution was added 300 mg of 10% palladium-on-carbon and the solution was catalytically reduced by bubbling hydrogen at ambient pressure for 60 minutes. The catalyst was filtered off and the methanol was removed by distillation under reduced pressure. The resulting residue was purified by column chromatography on silica gel using ethyl acetate as the eluent. This gives 0.35 g of the title compound as a crystalline solid, m.p. 149-150 ° C.

14th Example

N-Isobutyl-4- (benzyloxy) -3-nitro-cinnamic acid amide

The procedure of Example 1 was followed, but using 400 mg of isobutylamine to give 850 mg of the title compound, m.p. 166-167 ° C.

15th Example

N-isobutyl-3- (4-hydroxy-3-aminophenyl) propionamide

Following the procedure of Example 13, however, 800 mg of N-isobutyl-4- (benzyloxy) -3-nitro-cinnamic acid amide prepared in Example 14 were used to obtain 600 mg of the title compound as an oily substance.

Rf = 0.19 (eluent: ethyl acetate).

16th Example

N- (2,4-Dichlorophenyl -) - 4- (benzyloxy) -3-nitro-cinnamide

The procedure described in Example 12 was followed, but using 600 mg of 2,4-dichloroaniline to give 900 mg of the title compound, m.p. 152-153 ° C.

17th Example

N- (2,4-Dichlorophenyl) -3- (4-hydroxy-3-aminophenyl) propionamide

The procedure described in Example 13 was followed, but using 850 mg of N- (2,4-dichlorophenyl) -4- (benzyloxy) -3-nitro-cinnamic acid amide from Example 16, giving 650 mg of the title compound. mp 130-131 ° C.

18th Example

N- (2,5-dimethylphenyl) -4- (benzyloxy) -3-nitro-fahéisavamid

Following the procedure of Example 12, 600 mg of 2,5-dimethylaniline were reacted to give 850 mg of the title compound as an oily substance.

Rf 0.90 (eluent: ethyl acetate).

19th Example

N- (2,5-Dimethyl-phenyl) -3- (4-hydroxy-3-aminophenyl) -propionamide

The procedure described in Example 13 was followed, but 800 mg of N- (2,5-dimethylphenyl) -4- (benzyloxy) -3-nitrocinnamic acid amide prepared in Example 18 were reacted to give 600 mg of the title compound. m.p. 162-163 ° C.

20th Example

N- (1-Adamantyl) -3-? 3-nitro-4- (trifluoroacetamido) phenyl 1-propionamide Ig, 3- [3-Nitro-4- (trifluoroacetamido) - prepared according to Reference Example 5 - phenyl] propionic acid was dissolved in 30 ml of methylene chloride. For the resulting solution 1:

Add 60 drops of dimethylformamide, cool to 0 ° C and add 3 g of oxalyl chloride. After the temperature was raised to the ambient temperature, the mixture was stirred for 2 hours. The solvent was then completely removed by distillation under reduced pressure and the residue was dissolved in methylene chloride (20 mL). After addition of 0.6 g of 2-adamantylamine and 0.4 g of triethylamine, the reaction mixture is stirred for 3 hours. After 3 hours, the solution was diluted with ethyl acetate, which was then washed with water, dilute aqueous sodium bicarbonate and saturated aqueous sodium chloride, respectively. The organic layer was separated and dried over anhydrous sodium sulfate, and the solvent was removed by distillation under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate). 1.0 g of the title compound is isolated in the form of an oily substance.

Rf = 0.71 (eluent: ethyl acetate).

21st Example

N- (1-adamantyl) -3- (3-nitro-4-aminophenyl) propionamide

0.5 g of N- (1-adamantyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide prepared in Example 20 are dissolved in 10 ml of methanol. To the solution was added 10 ml of 2N aqueous sodium hydroxide solution and the mixture was stirred for 3 hours at room temperature. After 3 hours, methanol was distilled off under reduced pressure. The residue was extracted with ethyl acetate to give the title compound as an oily substance.

Rf value: 0.38 (eluent: ethyl acetate: hexane 1: 1 ··· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ··

- 61% by volume).

22nd Example

N- (1-adamantyl) -3- (3,4-diamino-phenyl) -propionamide

500 mg of N- (1-adamantyl) -3- (3-nitro-4-aminophenyl) propionamide, prepared as described in Example 21, is dissolved in 20 ml of methanol. 200 mg of a 10% palladium-on-carbon catalyst are added to the solution and then catalytically reduced by bubbling hydrogen at ambient pressure for 120 minutes. The catalyst was removed by filtration and the methanol was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate: methanol = 19: 1). 0.21 g of the title compound is obtained as a crystalline solid, m.p. 151-152 ° C.

23rd Example

N- (2,4-Dichlorophenyl) -3-r3-nitro-4- (trifluoroacetamido) propionamide To a suspension -fenil1

Following the procedure of Example 20, however, 800 mg of 2,4-dichloroaniline is reacted to give 800 mg of the title compound, m.p. 193-184 ° C.

24th Example

N- (2,4-Dichlorophenyl) -3- (3-nitro-4-aminophenyl) propionamide

Example 21 was followed by the reaction of 700 mg of N- (2,4-dichlorophenyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide prepared in Example 23, 350 mg of the title compound are obtained, m.p. 164-165 ° C.

25th Example

N- (2,4-Dichlorophenyl) -3- (3,4-diamino-phenyl) -propionamide

Following the procedure of Example 22, 300 mg of N- (2,4-dichlorophenyl-3- (3-nitro-4-aminophenyl) -propionamide, prepared as described in Example 24, are reacted to give 150 mg. of the title compound, m.p. 149-150 ° C.

26th Example

N- {3- [3-Nitro-4- (trifluoroacetamido) -phenyl] -propionyl · -morpholine

The procedure described in Example 21 was followed, however, by reaction of 400 mg of morpholine to give 900 mg of the title compound as an oily substance.

Rf value: 0.50 (eluent: ethyl acetate).

27th Example

Γ3- N- (3-Nitro-4-aminophenyl) propionyl morpholine

Following the procedure of Example 21, however, 800 mg of N- {3- [3-nitro-4- (trifluoroacetamido) phenyl] propionyl} morpholine, prepared in Example 26, were reacted to give 600 mg of the title compound. obtained in the form of an oily substance.

Rf value: 0.50 (1: 1 v / v ethyl acetate / hexane).

28th Example

Ν-Γ3- (3,4-Diamino-phenyl) propionyl-morpholine

Following the procedure of Example 22, 500 mg of N- [3- (3-nitro-4-aminophenyl) -propionyl] -morpholine, prepared in Example 27, are reacted to give 300 mg of the title compound, an oil. material.

Rf = 0.37 (4: 1 v / v ethyl acetate: methanol).

29th Example

N, N-Diethyl-3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide

The procedure described in Example 20 was followed, but 400 mg of diethylamine was reacted to give 1000 mg of the title compound as an oily substance.

Rf 0.70 (eluent: ethyl acetate).

30th Example

N, N-Diethyl-3- (3-nitro-4-aminophenyl) propionamide

Following the procedure of Example 21, however, 900 mg of N, N-diethyl-3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide prepared in Example 29 were reacted to give 600 mg of the title compound. mp 98-99 ° C.

31st Example

N, N-Diethyl-3- (3,4-diamino-phenyl) -propionamide

Following the procedure described in Example 22, however, 550 mg of N, N-diethyl-3- (3-nitro-4-aminophenyl) propionamide prepared in Example 30 are reacted to give 300 mg of the title compound as a crystalline solid. form.

Rf 0.53 (eluent: ethyl acetate / methanol = 4: 1, v / v).

32nd Example

N- (3-Quinolyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide

Following the procedure of Example 20, however, 700 mg of 3-aminoquinoline were reacted to give 900 mg of the title compound as an oily substance.

Rf value: 0.50 (eluent: ethyl acetate).

33rd Example

N- (3-Quinolyl) -3- (3-nitro-4-aminophenyl) propionamide

Following the procedure of Example 21, however, 850 mg of N- (3-quinolyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide, prepared in Example 32, are reacted to give 600 mg of the title compound. m.p. 219.5-220.5 ° C.

34th Example

N- (3-Quinolyl) -3- (3,4-diamino-phenyl) -propionamide

Following the procedure of Example 22, 500 mg of N- (3-quinolyl) -3- (3-nitro-4-aminophenyl) -propionamide prepared in Example 33 are reacted to give 300 mg of the title compound material.

Rf 0.42 (eluent: ethyl acetate / methanol = 4: 1).

35th Example

N- (2,5-Dimethyl-phenyl) -3- [3-nitro-4- (trifluoro-acetamido) -phenyl] -propionamide

Following the procedure of Example 20, however, 600 mg of 2,5-dimethylaniline was reacted to give 900 mg of the title compound as an oily substance.

Rf value: 0.45 (1: 1 v / v ethyl acetate / hexane).

• · · * · · · · · · · · · · · · · · · · · · · · · · · · · ·

36th Example

N- (2,5-Dimethyl-phenyl) - (4-amino-3-nitrophenyl) -propionamide

Following the procedure of Example 21, however, 800 mg of N- (2,5-dimethylphenyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide, prepared in Example 35, This gives 600 mg of the title compound, m.p. 187-188 ° C.

37th Example

N- (2,5-Dimethyl-phenyl) - (3,4-diaminophenyl-propionamide)

The procedure described in Example 22 was followed, but 500 mg of N- (2,5-dimethylphenyl) - (4-amino-3-nitrophenyl) propionamide prepared in Example 36 were reacted to give 300 mg of the title compound. m.p. 120-121 ° C.

38th Example

N, N-Diphenyl-3-r3-nitro-4- (trifluoroacetamido) -fenil1 propionamide

Following the procedure described in Example 20, however, 600 mg of diphenylamine are reacted to give 950 mg of the title compound as an oily substance.

Rf 0.56 (1: 1 v / v ethyl acetate / hexane).

39th Example

N, N-Diphenyl-3- (4-amino-3-nitro-phenyl) -propionamide

Following the procedure of Example 21, however, 900 mg of N, N-diphenyl-3- [3-nitro-4- (tri66-fluoroacetamido) -phenyl] -propionamide prepared in Example 38 were reacted to give 750 mg of the title compound. m.p. 189-190 ° C.

40th Example

N, N-Diphenyl-3- (3,4-diamino-phenyl) -propionamide

Following the procedure described in Example 22, however, 600 mg of N, N-diphenyl-3- (4-amino-3-nitrophenyl) propionamide prepared in Example 39 were reacted to give 300 mg of the title compound, m.p. 122-123 ° C.

41st Example

N- (4-Benzoyl-phenyl) -3- [3-nitro-4- (trifluoro-acetamido) -phenyl] -propionamide

Following the procedure of Example 20, however, 800 mg of 4-benzoyl aniline was reacted to give 1.1 g of the title compound as an oily substance.

Rf value: 0.63 (3: 2 v / v ethyl acetate / hexane).

42nd Example

N- (4-Benzoyl-phenyl) -3- (4-amino-3-nitro-phenyl) -propionamide

Following the procedure described in Example 21, however, 1.0 g of N- (4-benzoylphenyl) -3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide, prepared in Example 41, are reacted. yield 800 mg of the title compound, m.p. 72-73 ° C.

43rd Example

N- (4-Benzoyl-phenyl) -3- (3,4-diamino-phenyl) -propionamide

Following the procedure of Example 22, however, 700 mg of N- (4-benzoylphenyl) -3- (4-amino-3-nitrophenyl) propionamide prepared in Example 42 were reacted to give 500 mg of the title compound. mp 156-157 ° C.

44th Example

N- [3- (3-Nitro-4- (trifluoroacetamido) phenyl] propionyl} piperidine

Following the procedure of Example 20, 400 mg of piperidine were reacted to give 800 mg of the title compound, m.p. 102-103 ° C.

45th Example

N- [3- (4-Amino-3-nitrophenyl) propionyl] piperidine

Following the procedure of Example 21, however, 700 mg of N- {3- [3-nitro-4- (trifluoroacetamido) phenyl] propionyl} piperidine, prepared in Example 44, are reacted to give 500 mg of the title compound. mp 140-141 ° C.

46th Example

Γ3- N- (3,4-Diamino-phenyl) propionyl-piperidine

Following the procedure of Example 22, 400 mg of N- [3- (4-amino-3-nitrophenyl) -propionyl] -piperidine, prepared in Example 45, are reacted to give 200 mg of the title compound as an oil.

Rf value: 0.37 (9: 1 v / v ethyl acetate: methanol).

47th Example

N-Methyl-N-phenyl-3- [3-nitro-4- (trifluoroacetamido) -phenyl] -propionamide

Following the procedure of Example 20, however, 500 mg of N-methylaniline was reacted to give 1.1 g of the title compound as an oily substance.

Rf value: 0.40 (1: 1 v / v ethyl acetate: n-hexane).

48th Example

N-Methyl-N-phenyl-3- (4-amino-3-nitrophenyl) -propionamide

Following the procedure of Example 21, however, 900 mg of N-methyl-N-phenyl-3- [3-nitro-4- (trifluoroacetamido) phenyl] propionamide, prepared in Example 47, are reacted to give 700 mg of the title compound. The title compound is obtained as an oily substance.

Rf value: 0.33 (9: 1 v / v ethyl acetate / hexane).

49th Example

N-Methyl-N-phenyl-3- (3,4-diamino-phenyl) -propionamide

Following the procedure described in Example 22, however, 600 mg of N-methyl-N-phenyl-3- (4-amino-3-nitrophenyl) -propionamide prepared in Example 48 were reacted to give 400 mg of the title compound. in the form of an oily substance.

Rf value: 0.47 (1: 1 v / v ethyl acetate: methanol).

50th Example

N- (3-Quinolyl) -3- (3,4-diamino-phenyl) -propionamide hydrochloride · · · · · To a solution of N- (3-quinolyl) -3- (3,4-diaminophenyl) -propionamide prepared in Example 34 in 20 ml of methanol under ice-cooling is added 5 ml of 4 N. a solution of hydrogen chloride in dioxane was added and the solvent was distilled off. The residue was crystallized from a mixture of methanol and diethyl ether to give 0.7 g of the desired compound, m.p. 246-247 ° C.

51st Example

N- (1-indanyl) -4-acetoxy-3-nitro-fahéisavamid

The procedure of Example 1 was followed, however, by reacting 600 mg of 1-indanylamine to give 1.0 g of the title compound, m.p. 177-178 ° C.

52nd Example

N- (1-indanyl) -4-hydroxy-3-nitro-fahéisavamid

Following the procedure of Example 2, however, 900 mg of the N- (1-indanyl) -4-acetoxy-3-nitro-cinnamic acid amide prepared in Example 51 were reacted to give 700 mg of the title compound, m.p. They are C's.

53rd Example

N- (1-indanyl) -3- (4-hydroxy-3-aminophenyl) propionamide

Following the procedure of Example 3, however, 600 mg of N- (1-indanyl) -4-hydroxy-3-nitro-cinnamic acid amide prepared in Example 52 were reacted to give 400 mg of the title compound, m.p. 130-131 ° C. are.

54th Example

N-f4-acetoxy-3-nitrocinnamoyl) morpholine

The procedure described in Example 1 is followed, however, with 400 mg · ··· 4 · ·······································• Morpholine was reacted to give 900 mg of the title compound as an oily substance.

Rf value: 0.24 (1: 1 v / v ethyl acetate: hexane).

55th Example

N- (4-Hydroxy-3-nitrocinnamoyl) morpholine

Following the procedure of Example 2, however, 800 mg of N- (4-acetoxy-3-nitrocinnamoyl) -morpholine from Example 54 were reacted to give 600 mg of the title compound as an oily substance.

Rf value: 0.24 (1: 1 v / v ethyl acetate: hexane).

56th Example

N- [3- (4-Hydroxy-3-aminophenyl) -propionyl] -morpholine

Following the procedure of Example 3, however, 500 mg of N- (4-hydroxy-3-nitro-cinnamoyl) -morpholine from Example 55 were reacted to give 400 mg of the title compound as an oil.

Rf = 0.27 (eluent: ethyl acetate).

First PREPARATION

4-Hydroxy-3-nitro-fahem ~ ISAV

16.7 g of 4-hydroxy-3-nitrobenzaldehyde and 33.5 g of methyl triphenylphosphoranylidene acetate are dissolved in 100 ml of methylene chloride and the resulting solution is stirred at room temperature for 2 hours. After 2 hours, the solvent was removed by distillation under reduced pressure. To the residue thus obtained was added methanol (300 ml) and sodium hydroxide (18 g), and the solution was refluxed for 2 hours. The methanol is then distilled off under reduced pressure. The residue is taken up in 1 liter of water and the insoluble material is filtered off. The filtrate was acidified with 3N aqueous hydrochloric acid and the precipitated crystals were collected by filtration and dissolved in 500 ml of tetrahydrofuran. Activated carbon was added to the solution, refluxed for 5 minutes, and filtered while still hot. The solution was concentrated under reduced pressure for approx. It is concentrated to 100 ml and allowed to stand at room temperature. 15.0 g of the title compound are obtained in the form of a yellow solid.

Second PREPARATION

4-Acetoxy-3-nitro-cinnamic acid g, 4-hydroxy-3-nitro-cinnamic acid prepared in Reference Example 1 was dissolved in 30 ml of acetic anhydride. After adding a drop of sulfuric acid, the solution was stirred at room temperature for 2 hours. Water (50 mL) was added and stirring was continued for a further 2 hours. After stirring, the mixture was diluted with ethyl acetate and washed with water and a saturated aqueous sodium chloride solution, respectively, and then dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and toluene was added to the residue; the remaining acetic acid was removed by azeotropic distillation to give 10.2 g of the title compound as crystals.

Third PREPARATION

Ethyl 4- (acetylamino) -phenyl propionate · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · What to English Ethyl 4-nitrocinnamate (··· · · g) was dissolved in acetic acid (100 mL) and 1 g palladium on carbon (10%) was added and the solution was catalytically reduced by bubbling hydrogen at ambient pressure for 60 minutes. The catalyst was then removed by filtration and the acetic acid was distilled off under reduced pressure. The residue thus obtained was mixed with 50 ml of acetic anhydride and the resulting solution was allowed to stand overnight at room temperature. The solvent was then distilled off under reduced pressure. Purification by column chromatography on silica gel gave 7.8 g of the title compound in crystalline form.

4th PREPARATION

3- (4-Amino-3-nitrophenyl) propionic acid g, Ethyl 4- (acetyl) aminophenylpropionate prepared in Reference Example 3 was dissolved in 30 mL acetic acid and 30 mL acetic anhydride. 10 ml of fuming nitric acid of 1.5 specific gravity are added dropwise at 40 [deg.] C., which is approx. It takes 1 hour. The reaction mixture was then added dropwise to 300 ml of ice water. The precipitated crystals were collected by filtration and then refluxed for 4 hours after adding 30 ml of concentrated hydrochloric acid and 30 ml of acetic acid. The solvent was then removed by distillation under reduced pressure. Purification by chromatography on a silica gel column using ethyl acetate as the eluent gave 2.2 g of the title compound as an oil.

The product had an Rf of 0.62 on a thin layer of silica gel using ethyl acetate as the eluent.

• · ····· · · · • · · · · · · •· · ··· · ·

5th PREPARATION

3- [3-Nitro-4- (trifluoroacetamido) phenyl] propionic acid g, 3- (4-Amino-3-nitrophenyl) propionic acid prepared in Reference Example 4 is dissolved in 10 ml of trifluoroacetic anhydride. The solution was then stirred at room temperature for 2 hours, then mixed with ethyl acetate, washed with water and brine, and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, the residue was mixed with toluene and the remaining trifluoroacetic acid was removed by azeotropic distillation. This gave 1.5 g of the title compound as a crystalline solid.

Preparation Example

Production of capsules

The following components are thoroughly mixed in a powdered state and passed through a 60 mesh sieve (Tyler standard):

N- (1-Adamantyl) -3- (3-amino-4-hydroxyphenyl) propionamide (Example 3)

<td>produced according to)</td><td>25.0 mg</td>

<td>milk sugar</td><td>153.6 mg</td>

<td>corn starch</td><td>100.0 mg</td>

<td>Maqze ium stearate</td><td>1.4 m</td>

<td>altogether</td><td>280.0 mg</td>

The resulting 280 mg powder was filled into a gelatin capsule # 3.

22 members in 16 offices

This recordMember, by publication datePriority claim6 more offices are in the list below

Priority claims1

Priority claims
Document	Office	Kind	Date
2706091	Japan	A	1991-02-21

Members22

Family members, oldest first
Document	Office	Kind
HU9200579D0	Hungary	D0	1992-05-28
CA2061557A1	Canada	A1	1992-08-22
IE920538A1	Ireland	A1	1992-08-26
EP0501656A2	European Patent Office (EPO)	A2	1992-09-02
CN1064273A	China	A	1992-09-09
KR920016406A	Republic of Korea	A	1992-09-24
EP0501656A3	European Patent Office (EPO)	A3	1993-03-03
CZ50092A3	Czechia	A3	1993-03-17
JPH05112515A	Japan	A	1993-05-07
HUT64012AThis record	Hungary	A	1993-11-29
RU2042663C1	Russian Federation	C1	1995-08-27
EP0501656B1	European Patent Office (EPO)	B1	1997-01-22
AT148098T	Austria	T	1997-02-15
DE69216873D1	Germany	D1	1997-03-06
US5614521A	United States of America	A	1997-03-25
ES2099206T3	Spain	T3	1997-05-16
GR3022594T3	Greece	T3	1997-05-31
US5643925A	United States of America	A	1997-07-01
DK0501656T3	Denmark	T3	1997-07-21
DE69216873T2	Germany	T2	1997-08-21
CN1036064C	China	C	1997-10-08
HK1005722A1	Hong Kong, China	A1	1999-01-22

Process for producing benzene derivatives promoting nerve growth factor productiion, as well as pharmaceutical compositions comprising such active ingredient

Abstract

Term

Priority claims1

Members22

Events

Numbers

Titles

Classification